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Abstract

Women infected with the human immunodeficiency virus are at increased risk
for developing cervical cancer. Current guidelines reflect that Pap smears should be
performed twice during the first year after diagnosis with HIV and annually thereafter.
However, women with HIV are not obtaining Pap smears per the current guidelines. The
purpose of this study was to evaluate HIV-infected women’s attitudes toward cervical
cancer and cervical cancer screening. The research design is an exploratory, crosssectional, quantitative design. The sample of convenience consisted of participants
recruited from two ambulatory HIV clinics in Florida. Attitudes were assessed using
Champion’s Health Belief Model and Self-efficacy scales. Knowledge was evaluated
with an updated HPV/Cervical Cancer Knowledge scale. Sociodemographic variables
were assessed using a Demographic Data form. The results indicate that HIV-infected
women in the study were not knowledgeable about HPV or cervical cancer. They did not
perceive that cervical cancer was serious, nor did they feel that they were susceptible to
cervical cancer. Overall, HIV-infected women were confident in their ability to request a
Pap smear, and they perceived fewer barriers and more benefits to Pap smears. Despite,
perceptions of fewer barriers and more benefits a chart review revealed that
approximately 43% of the study participants received a Pap smear during the past year.
Perceived barriers was a significant predictor of Pap smear adherence (OR = 0.93, CI:

vii

0.90 to 0.96, p < .01). Findings from the exploratory study provide important information
to clinicians and researchers that will assist in the development of effective interventions
to increase Pap test adherence. Additional research is needed to further understand factors
that influence cervical cancer screening in this at-risk population.

viii

Chapter One: Introduction

Human Immunodeficiency Virus (HIV)-infected women are at an increased risk
for developing cervical dysplasia and cancer as a result of Human Papillomavirus (HPV)
-infection (ACOG, 2010; Tello et al., 2010; Aberg et al., 2009) because of their
compromised immune systems. The incidence and prevalence of HPV are high in HIVinfected women, especially those infected with high-risk types of HPV [11, 16, 18, 33,
51, 52, 53, 58 and 61] (De Vuyst, Lillo, Broutet & Smith, 2008; Clifford, Goncalves &
Franceschi, 2006). It is estimated that 12,700 women develop cervical cancer annually,
and approximately 4,200 women die as a result of cervical cancer (National Cancer
Institute [NCI], 2011; American Cancer Society [ACS], 2011). The most common cause
of cervical cancer is persistent infection with high-risk types of the HPV (NCI, 2011).
Precancerous cells caused by HPV can develop into invasive cervical cancer if the body’s
immune system does not clear the virus, the precancerous cells are not detected or the
precancerous cells are left untreated (NCI, 2011). In the early 1900s, cervical cancer was
the leading cause of death in women but the introduction of Papanicolaou (Pap) testing
drastically decreased mortality and morbidity rates secondary to cervical cancer (ACS,
2011). The Human Papillomavirus can be detected by HPV deoxyribonucleic acid (DNA)
testing, and precancerous cells (cervical dysplasia) can be detected by Pap testing (NCI,
2011). Cervical cancer screening via Pap testing is the recommended screening tool for
1

detecting cervical dysplasia (ACS, 2011; NCI, 2011; The American College of Obstetrics
and Gynecology [ACOG], 2010).
Persistent infection with HPV is common in women infected with HIV including
high-risk types and infection with multiple types which increases the risk of progression
to cervical cancer; thereby, making frequent Pap testing vital (De Vuyst et al., 2008;
Clifford et al., 2006). Current ACOG guidelines suggest conducting Pap testing every six
months during the first year after diagnosis or during the first year in care and annually
thereafter in women infected with HIV (ACOG, 2010).
However, HIV-infected women are not receiving Pap testing according to the
ACOG guidelines (Leece, et al., 2010). Studies have indicated that 19% to 25% of HIVinfected women had not received their annual Pap smear during the previous year
(Rahangdale, Sarnquist, Yavari, Blumenthal & Israelski, 2010; Tello et al., 2010; Oster,
Sullivan & Blair, 2009; Stein et al., 2001; Solomon et al., 1998), and about 75% had not
received the second recommended Pap test during their first year in care (Logan,
Khambaty, D’Souza & Menezes, 2010). Two other studies concluded that as many as
47% of HIV-infected women were not obtaining Pap smears annually (Baranoski et al.,
2011; Bazargan, Bazargan, Farooq & Baker 2004). Many reasons have been cited for
lack of Pap smear adherence.
Pain, lack of social support, lack of knowledge, lack of perceived susceptibility,
and previous negative experiences with healthcare providers have been identified as
factors associated with failure to adhere to Pap testing among women not infected with
HIV (Daley et al., 2011; Ackerson, Pohl & Low, 2008; Austin, Ahmad, McNally &
Stewart, 2002). Fear of cancer diagnosis and of discrimination, language barriers,
2

cultural beliefs, fatalistic attitudes and embarrassment were cited as factors that were seen
as barriers to cervical cancer screening (Daley et al., 2011; Tracy, Lydecker & Ireland,
2010; Watts et al., 2009; Lee-Lin et al., 2007; Warren, Londono, Wessel & Warren,
2006; Austin et al., 2002). Age data were mixed (Tracy et al., 2010; Watts et al., 2009;
Blackwell, Martinez & Gentleman, 2007; Lee-Lin et al., 2007; Datta et al., 2005; Hewitt,
Devesa & Breen, 2004). Lack of insurance was documented as another factor that serves
as a barrier (Daley et al., 2011; Peterson et al., 2008; Lee-Lin et al., 2007; Warren et al.,
2006: Gorin & Heck, 2004; Hewitt et al., 2004). Being of a specific ethnic group and
having less than high school education were associated with poor Pap test adherence
(Tracy et al., 2010; Peterson et al., 2008; Blackwell et al., 2007; Coughlin, King,
Richards & Ekwueme, 2006; Datta et al., 2005; Hewitt et al., 2004). Perceiving more
barriers and fewer benefits was associated with poor adherence (Tracy et al., 2010).
Transportation to the clinic was also cited as a factor (Daley et al., 2011). Obesity as
determined by body mass index (BMI) was a documented barrier, but obesity data were
mixed (Blackwell et al., 2007; Ferrante, Chen, Crabtree & Wartenberg, 2007; Datta et al.,
2005).
Factors that were associated with poor adherence to cervical cancer screening in
women infected with HIV include receiving a pelvic exam by a provider not managing
the woman’s HIV and low CD4+ T lymphocyte count (less than 200) (Baranoski et al.,
2011; Rahangdale et al., 2010; Logan et al., 2010; Oster et al., 2009; Tello et al., 2008;
Shah et al., 2006; Stein et al., 2001). Substance abuse, especially intravenous drug use,
lack of child care, insufficient social support, and lack of knowledge were identified as
factors that negatively affected Pap smear adherence in women infected with HIV (Logan
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et al., 2010; Tello et al., 2010; Tello et al. 2008; Andrasik, Rose, Pereira & Antoni, 2008;
Keiser et al., 2006). Negative attitudes toward providers, lack of providers’ knowledge of
current ACOG guidelines, poor provider-patient communication, extended wait times,
lack of continuity of care, and discomfort during Pap test were identified as factors that
hindered Pap testing in HIV-infected women (Logan et al., 2010; Andrasik et al., 2008;
Bazargan et al., 2004). Economic barriers including lack of insurance, financial
constraints, and lack of transportation influenced Pap testing (Tello et al., 2010; Tess &
Hackley, 2010; Andrasik et al., 2008; Bazargan et al., 2004). Pap testing was affected by
psychological barriers including fear of knowing the results, denial, depression and low
self-esteem (Tello et al., 2010; Andrasik et al., 2008). Data regarding the association of
age and Pap test adherence is mixed (Baranoski et al., 2011; Logan et al., 2010; Tello et
al., 2010; Tello et al., 2008; Oster et al., 2009; Keiser et al., 2006; Shah et al., 2006;
Bazargan et al., 2004). Having an HIV viral load of greater than 400 was associated with
not obtaining a Pap smear during the previous year (Keiser et al., 2006; Shah et al.,
2006). Having less education, inclement weather, and forgetting appointments were
factors that negatively affect Pap smear adherence (Tello et al., 2010; Keiser et al., 2006).
Not being white and being obese also were associated with poor Pap smear adherence in
HIV-infected women (Tess & Hackley, 2010; Keiser et al., 2006; Tello et al., 2008;
Bazargan et al., 2004).
Andrasik and colleagues (2008) interviewed HIV-infected African American
women regarding barriers to cervical cancer screening, and several women reported
having a lack of knowledge about reproductive health. During a thorough review of the
literature, no studies were found that assessed knowledge of cervical cancer and Pap
4

testing in women infected with HIV. No studies were found that examined perceived selfefficacy in discussing cervical cancer screening with a healthcare provider or being able
to request Pap testing. No studies have evaluated perceived susceptibility, perceived
seriousness, perceived benefits, or perceived barriers to cervical cancer screening in HIVinfected women; therefore, making this proposed study unique and an important addition
to the existent body of knowledge.
Purpose
The purpose of this study was to evaluate HIV-infected women’s knowledge of
and perceived susceptibility to cervical cancer, and their perception of the seriousness of
cervical cancer. Further, the study assessed their perceived self-efficacy, benefits, and
barriers to cervical cancer screening. In addition, predictors of cervical cancer screening
in HIV-infected women were evaluated.
Specific Aims
Aim one. Evaluated the relationship between Pap test adherence and the
following variables in: a) Champion’s Health Belief Model Scale (CHBM) and b)
Champion’s Self-efficacy (CSE) scale and c) HPV/cervical cancer knowledge scale.
Aim two. Evaluated the relationships between the following variables in: CHBM,
CSE, and knowledge scales, and selected sociodemographic variables.
Aim three. Assessed the ability of the variables in CHBM, CSE, and knowledge;
and select sociodemographic variables to predict Pap testing.
Conceptual Framework
The Health Belief Model (HBM) provided the theoretical base for this study. The
HBM was developed by psychologists in the U.S. Public Health Service in the 1950s as a
5

way to explain participation in medical prevention and disease detection programs
(Glanz, Rimer & Viswanath, 2008 as cited in Hochbaum 1958; Rosenstock, 1960, 1974).
The model was later expanded to explain the behavior of people in response to a medical
diagnosis such as cancer (Glanz et al., 2008 as cited in Becker, 1974).
According to Glanz, Rimer and Viswanath (2008) the HBM predicts the reason(s)
individuals take action to prevent, screen for and control illness; as in the case of Pap
testing in HIV-infected women. The HBM has been used to explain behaviors such as
tuberculosis screening, breast cancer screening, colon cancer screening, and risky sexual
behaviors (Glanz et al., 2008). A person’s beliefs, attitudes and perceptions about a
disease determine their actions to seek methods to prevent, screen for and control a
disease (Glanz et al., 2008). Intrapersonal factors such as knowledge, socio-economics
issues and age influence health behaviors (Glanz et al., 2008). The constructs of the
original HBM include perceived susceptibility, seriousness, benefits and barriers to a
specific behavior with the addition of cues to action and health motivation in the 1970s
and perceived self-efficacy in 1988. A valid instrument to measure cues to action does
not exist, and the concept is difficult to study in a survey (Glanz et al., 2008). However,
cues to action was evaluated in this study.
To help clarify the model, the definitions of the four original constructs, perceived
susceptibility, perceived seriousness, perceived benefits and perceived barriers to a
specific preventive action, are presented in the subsequent paragraph (Glanz et al., 2008).
The HBM implies that an individual’s perception of his/her susceptibility to a disease
coupled with his/her belief that the disease has potentially serious consequences
(perceived seriousness) equals the perceived threat which leads to a behavior such as Pap
6

testing. If the person believes that behaviors such as Pap testing are beneficial and
outweigh his/her perceived barriers, then he/she is more likely to adopt the new behavior.
The concept cues to action did appear in earlier diagrams of the HBM and it is considered
as a modifying variable (Glanz et al., 2008). Cues to action are events, people or things
that encourage people to change their behavior (Glanz et al., 2008). Examples of agents
of cues to action include family, friends, media, and health care providers (Glanz et al.,
2008). Other modifying variables include age, gender, ethnicity, personality,
socioeconomics, knowledge and motivation (Glanz et al., 2008). Health motivation was
introduced by Becker (1974) (as cited in Champion, 1984). Health motivation is a
concern about health (Champion, Skinner & Menon, 2005; Champion, 1984). Selfefficacy was added to the original four concepts in 1988 (Glanz et al., 2008). Selfefficacy is an individual’s belief that he/she can successfully accomplish a behavior
(Bandura, 1977). In combination with perceived susceptibility and seriousness, a person
must feel that he/she is capable of carrying-out a specific behavior and that the benefits of
the behavior outweigh the barriers. In addition, cues to action such as reminder letters or
reminder phone calls could lead to a specific outcome behavior. Figure 1.1 is a depiction
of a modified version of the HBM (Glanz et al., 2008).
Theoretical Definitions
Perceived susceptibility. The belief of a person about his/her chances of getting a
condition or disease (Glanz, Rimer and Viswanath, 2008).
Perceived seriousness. An individual’s belief about the severity of a disease
(Glanz et al., 2008).
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Figure 1 Modified Health Belief Model
Perceived benefits. A person’s belief that the new behavior will reduce his/her
risk of a disease (Glanz et al., 2008; Champion 1993)
Perceived barriers. The belief of a person about obstacles that may prevent them
from a specific action (Glanz et al., 2008).
Perceived self-efficacy. A person’s belief or confidence in his/her ability to take
action or adapt a specific behavior (Glanz et al., 2008; Champion, Skinner & Menon,
2005).
Cues to action. Factors that will trigger a person to adopt a new behavior (Glanz
et al., 2008).
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Health motivation. A state of concern about general health issues (Champion,
1984).
HPV/Cervical cancer knowledge. The information that an individual knows
about the causes, risk factors, mode of transmission, screening tools and methods of
prevention regarding cervical cancer.
Adherence to guidelines. In 2010, the American College of Obstetrics and
Gynecology (ACOG) developed guidelines for gynecologic care specific to women
infected with HIV. The guidelines state that HIV-infected women must receive two Pap
test the first year after diagnosis and then Pap testing every year (ACOG, 2010).
Significance
Infection with HPV increases HIV-infected women’s risk of developing cervical
dysplasia; particularly, if the virus is left untreated (ACOG, 2010; Tello et al., 2010;
Aberg et al., 2009). A significant number of studies have established that certain barriers
exist as failures to adhere to pap testing in the general population. However, limited
research addresses factors affecting cervical cancer screening in HIV infected women.
Clinicians could identify patients at risk for poor Pap test adherence with a better
understanding of HIV-infected women’s perception of their susceptibility and
vulnerability to developing cervical cancer; in addition to, the benefits, barriers and
knowledge of women infected with HIV, with regard to receiving cervical cancer
screening. Based on the review of available research, clinicians are in need of
information that can be used to identify factors affecting cervical cancer screening in HIV
infected women.
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Summary
Cervical cancer is caused by untreated cervical dysplasia or abnormal cervical cell
changes which are commonly caused by HPV. Pap testing is the recommended screening
tool to detect cervical cell changes. HIV-infected women have an increased risk of
developing cervical cancer and ACOG has released recommended cervical cancer
screening guidelines which are different from the guidelines of women not infected with
HIV. HIV-infected women are not receiving Pap testing at the recommended intervals
and numerous barriers to receiving Pap testing have been documented. A survey study
was proposed to evaluate factors that influence cervical cancer screening in HIV-infected
women. The proposed study may enhance the knowledge of clinicians caring for HIVinfected women and motivate researchers to assess interventions that will improve
cervical cancer knowledge and awareness; as well as, eliminate or lessen barriers to
cervical cancer screening. This research is important to clinicians, researcher and women
infected with HIV.
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Chapter Two: Literature Review

Note to Reader
Portions of the review of literature have been previously published (Chapman
Lambert, 2012) and are utilized with permission of the publisher.

Chapter two of the dissertation proposal is a presentation of the review of
literature concerning the human papillomavirus (HPV), cervical cancer, cervical cancer
screening guidelines for HIV-infected women and sociodemographic factors that
influence cervical cancer screening. In addition, information is presented about the
perceived susceptibility, severity, benefits, barriers and self-efficacy to cervical cancer
and cervical cancer screening. The information presented about HPV and cervical cancer
was retrieved from the following websites: ACS, AIDS Healthcare Foundation, CDC,
NCI and WHO. The following search engines were utilized to search for articles:
CINAHL, PubMed and PsychINFO. Keywords in different combinations were used to
retrieve articles: cervical cancer, screening, Pap smear, Pap test, prevention, barriers,
HIV, AIDS, HBM, cervical dysplasia, and HPV. Additional articles were selected from
the reference pages of studies identified in the initial search. The material presented
builds a case for the significance of the proposed study.
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Human Papillomavirus
HPV is a group of more than 150 types of the virus, of which 40 are known to be
sexually transmitted (CDC, 2010b; NCI, 2011a). The 40 viruses that are sexually
transmitted can cause genital warts or cervical cancer. An infected person can transmit
these viruses to his/her partner(s) via vaginal, anal, or oral sexual intercourse in the
absence of symptoms and while using condoms (CDC, 2010b; NCI, 2011a). Genital HPV
infections are common and usually occur and resolve without symptoms after a few years
(NCI, 2011a). Alarmingly, HPV is so common that about 50% of Americans will be
infected at some time in their lives (NCI, 2011a). Persistent infection with HPV can cause
precancerous cells (cervical dysplasia), and, when left untreated, cancers of the vagina,
vulva, penis, anus, and oropharynx may develop (CDC, 2010b). Women infected with
HIV are more likely to be infected with multiple types of HPV, are less likely to have the
virus cleared by their weakened immune systems, and are more likely to develop cancer
(Clifford, Goncalves, & Franceshi, 2006; De Vuyst, Lillo, Broutet, & Smith, 2008).
HPV Vaccines
In an effort to prevent cervical cancer, the U. S. Food and Drug Administration
approved two vaccines, Gardasil® and Cervarix®. Both vaccines are effective against
high-risk HPV types 16 and 18 (CDC, 2011). In addition, Gardasil® is effective against
HPV types 6 and 11, which are responsible for most genital wart infections (CDC, 2011).
Gardasil® is licensed for females and males ages 9 to 26 years and Cervarix® is licensed
for females ages 9 to 26 years (CDC, 2011). The CDC (2011) recommends vaccine
administration beginning at ages 11 or 12 years, with 9 years being the minimum age
allowed. The CDC (2011) has emphasized that HPV vaccines do not cure or treat existing
12

infections, but women with a history of cervical dysplasia (abnormal Pap result) should
receive the vaccine in accordance with the current CDC guidelines.
Cervical Cancer
Cervical cancer starts at the lower part of a woman’s uterus (NCI, 2008). There
approximately 15 types of high risk HPV, with HPV 16 and 18 being the most common,
Persistent infections with high-risk HPV types can progress to cervical cancer (NCI,
2011a). Globally, more than 500,000 women have been estimated to be diagnosed with
HPV-related cervical cancer annually with 80% of cases occurring in developing
countries (WHO, 2011). The NCI (2011a) has predicted that each year more than 12,000
women in the United States will be diagnosed with HPV-related cervical cancer and more
than 4,000 will die. Risk factors for cervical cancer, in addition to HPV, include using
tobacco, being immune compromised, giving birth to three or more children, and being
on oral contraception for more than 5 years (CDC, 2010a; NCI, 2011a). Women with
early stage cervical cancer rarely have symptoms. It is not until the cancer progresses that
women experience abnormal vaginal bleeding between menstrual periods, after
intercourse, after menopause, or after pelvic examinations (NCI, 2011a). Cervical cancer
screenings can detect abnormal cells or pre-cancerous cells early, allowing treatment to
be initiated.
Cervical Cancer in HIV-Infected Women
Cervical cancer is considered an AIDS-defining cancer in individuals infected
with HIV (AIDS Healthcare Foundation, 2008). Infection with HIV weakens the immune
system leaving an individual vulnerable to a number of cancers (NCI, 2011b). The risk of
cervical cancer in HIV-infected women is greater than the risk in uninfected women due
13

the immune system’s limited ability to fight HPV (AIDS Healthcare Foundation, 2008;
ACOG, 2010; NCI, 2011b). The introduction of effective antiretroviral therapy (ART)
has decreased the incidence of Kaposi’s sarcoma and non-Hodgkin’s lymphoma, but
ART has not decreased the incidence of cervical cancer, and the reason for this is not
well understood (NCI, 2011b). Women co-infected with HIV and HPV, with HPVrelated cervical cancer, and with CD4+ T lymphocyte counts less than 200 cells/mm3
have a risk of poorer outcomes (AIDS Healthcare Foundation, 2008). Women with CD4+
T lymphocyte counts less than 50 cells/mm3 are at higher risk of the cervical cancer
returning after treatment (AIDS Healthcare Foundation, 2008).
Screening Guidelines in HIV-Infected Women
Routine cervical cancer screenings with Pap test and follow-up treatment reduces
mortality in all women. Secondary to higher incidences of cervical cancer in women
infected with HIV, screening guidelines for HIV-infected women differ in frequency
from those of uninfected women. Women infected with HIV should receive two Pap tests
the first year after diagnosis or during the first year in care, and annually thereafter
(ACOG, 2010). According to Armas and colleagues (2007), HIV-infected women also
should receive at least two cervical cancer screenings, 6 months apart, after changing
sexual partners, and annually thereafter if the results are normal. Cervical cancer
screening should begin at age 21 (ACOG, 2009). It is appropriate to discontinue
screening after age 65 in women who have had three or more negative Pap test in a row
and in women without a history of abnormal test results in the previous 10 years (ACOG,
2009). Women 65 years of age and older who are sexual active and have multiple sex
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partners should continue to be screened per ACOG guidelines (ACOG, 2009). Clinicians
should continue to conduct risk assessments after discontinuing screening (ACOG, 2009).
Factors that Influence Cervical Cancer Screening
Many factors that affect cervical cancer screening are common to all women, but
there are factors that solely affect HIV-infected women. Factors such as age, tobacco use,
weight, race/ethnicity, education, economics, and risky sexual behaviors have been cited
as affecting cervical cancer screening in all women. Serologic values such as HIV viral
load and CD4+ T lymphocyte count are factors unique to women infected with HIV.
Age. The majority of the articles agreed that older women were more likely to
have poor Pap test adherence. A chart review of women ages 18 to 60 at a large urban
HIV clinic revealed that older age was associated with inadequate Pap testing (Baranoski,
Horsburgh, Cupples, Aschengrau, & Stier, 2011). Two hundred women attending the
Johns Hopkins HIV clinic were surveyed about Pap test adherence and the results
revealed that women 50 years of age and older were less likely to adhere to Pap testing
(Tello et al., 2010). The Swiss HIV Cohort Study was developed to evaluate factors
associated with frequency of gynecologic follow-up and cervical cancer screening. Older
age was a predictor of fewer gynecologic examinations and Pap smears (Keiser et al.,
2006). As age increased, women were less likely to receive a Pap test (Oster, Sullivan, &
Blair, 2009). Although older age has been consistently linked to poor Pap test adherence,
one study conducted in an HIV clinic in San Mateo, California from January 2002 to
December 2006 did not find an association between age and Pap test adherence
(Rahangdale, Sarnquist, Yavari, Blumenthal, & Israelski, 2010).
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In uninfected women, age data consistently found that older age was associated
with poor Pap test adherence. In a sample of 255 lesbian women, older age was a
predictor of adherence to routine cervical cancer screening (Tracy, Lydecker, & Ireland,
2010). Women 30 years of age and older were less likely to report Pap smear screening in
a study with 318 participants, ages 18 to 99 (Watts et al., 2009). Blackwell, Martine, and
Gentleman (2007) conducted a secondary analysis using information from the Joint
Canada/United States Survey of Health. The study examined Pap testing in Canadian and
U.S. women during 2002 and 2003. Women ages 40 to 59 were less likely to be adherent
to Pap testing than women ages 18 to 29. In women 40 years of age and older living in
the southeastern United States, being 65 years of age or older was a factor that negatively
influenced adherence to Pap testing (Peterson, Murff, Cul, Hargreaves, & Fowke, 2008).
In 2005, using data from the National Health Interview Survey (NHIS), a sample of
Latina women were surveyed about their use of Pap smears, and Latinas ages 50 years
and older were less likely to have had a Pap test within the previous year (Gorin & Heck,
2005). Among 230 African-American and Latino women living in an urban housing
development in Los Angeles County, women ages 45 years and older were less likely to
have had a Pap smear within the 12 months before the study (Bazargan, Bazargan,
Farooq, & Baker, 2004). Another study analyzed the NHIS data and concluded that
women of various ethnicities 65 years of age were less likely to be receiving Pap testing
(Hewitt, Devesa, & Breen, 2004). Among Appalachian women, Pap testing was less
common in women ages 65 years and older (Hall, Uhler, Coughlin, & Miller, 2002).
From the information reported here, it can be inferred that older women are less likely to
receive Pap testing than younger women.
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Ethnicity/race. Ethnicity data were not consistent. A chart review of a large
urban HIV clinic concluded that being White or Hispanic increased the odds of not
having had a Pap test (Baranoski et al., 2011). In a prospective chart review conducted at
the Johns Hopkins HIV Clinic from January 2002 to April 2006, women who were
African American were less likely to attend gynecological appointments than Caucasian
women (Tello et al., 2008). Among the Swiss study cohort, being of non-White ethnicity
was associated with fewer Pap smears (Keiser et al., 2006).
In uninfected women, being Black or African American has been shown to be a
positive predictor of Pap test adherence (Bazargan et al., 2004; Blackwell et al., 2007;
Hewitt et al., 2004; Peterson et al., 2008; Selvin & Brett, 2003). In a secondary analysis
of the Southern Community Cohort Study, Peterson and colleagues (2008) examined Pap
testing among women from low socioeconomic and education backgrounds. African
American women had the highest cervical cancer screenings rates. In a sample of more
than 5,000 U.S. women ages 18 years and older who participated in the Joint
Canada/United States Survey of Health, non-Hispanic Black women were more likely to
be compliant with Pap testing guidelines than non-Hispanic White women (Blackwell et
al., 2007). Among the 13,745 women surveyed in the 2000 National Health Interview
Survey, being African American relative to non-Hispanic White was associated with
greater Pap test use (Hewitt et al., 2004).
Tobacco use. Among HIV-infected women, research has indicated that women
who smoke cigarettes are more like to have poor Pap test adherence. Being a current
smoker was a predictor of fewer gynecologic examinations and Pap smears (Keiser et al.,
2006). An analysis of charts at Boston Medical Center found that HIV-infected women
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who were current or former cigarette smokers had a decreased likelihood of having had a
Pap test during 18 months of follow-up (Baranoski et al., 2011).
Among uninfected women, data regarding the association of poor Pap smear
adherence and cigarette use were mixed. Two research studies determined that cigarette
smokers were more likely to comply with cervical cancer adherence (Blackwell et al.,
2007; Selvin & Brett, 2003). However, Hewitt and colleagues (2004) concluded that
cigarette smokers were less likely to adhere to cervical cancer screening (Datta et al.,
2006). Datta and colleagues (2006) analyzed data from the Black Women’s Health Study,
which included approximately 59,000 women from across the United States who ranged
in age from 21 to 69. Smokers had a greater prevalence of non-adherence to Pap testing
than nonsmokers (Datta et al., 2006). Hewitt and colleagues (2004) analyzed data from
the 2000 NHIS, which included about 13,700 participants 18 years of age and older.
Among women ages 25 to 44 years, being a former smoker was associated with greater
Pap test use (Hewitt et al., 2004). An analysis of the 1998 National Health Interview
Survey data revealed that current smokers were less likely to report a recent Pap test,
which remained consistent across ethnicities (Selvin & Brett, 2003).
Weight. No U.S.-based studies were found that assessed the association between
body mass index (BMI) and Pap test adherence in HIV-infected women. In the Swiss
cohort, women who were underweight, which was defined as a BMI of less than 18
kg/m2, were more likely to have had fewer Pap smears (Keiser et al., 2006. Being obese
and having a BMI greater than 35 kg/m2 were predictors of fewer Pap smears in women
participating in the Swiss cohort study (Keiser et al., 2006).
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More US-based studies have linked obesity to poor adherence to Pap testing in
uninfected women; however, the data are mixed. Two studies found that obese women
are less likely to participate in cervical cancer screening (Datta et al., 2006; Ferrante,
Chen, Crabtree, Wartenberg, 2007). Women with a BMI of greater than 30 kg/m2 were
less likely than women with a BMI between 20 kg/m2 and 29 kg/m2 to adhere to Pap
screening (Datta et al., 2006). Data from the 2000 National Health Interview Survey
revealed that U.S. women ages 40 to 74 years with a BMI greater than 30 kg/m2 were less
likely to adhere to Pap smears (Ferrante et al., 2007). Two literature reviews using
articles from 1990 through 2009 suggest that obesity negatively affected Pap screening in
White women (Aldrich & Hackley, 2010; Cohen et al., 2008). In contrast, one study
found no association between weight and adherence (Blackwell et al., 2008).
Education. Poor Pap test adherence was associated with having less than a high
school education (Del Maso et al., 2010; Keiser et al., 2006; Tello et al., 2010). A crosssectional study conducted in Northern Italy between July 2006 and June 2007 included
1,002 HIV-infected women. The goal of the study was to assess factors associated with
adherence to cervical cancer screening during a one-year period. Women with less than a
high school education were less likely to report having a Pap in the year before the
questionnaire (Del Maso et al., 2010). Another study examined barriers to adherence to
gynecologic care in 200 women at the Johns Hopkins HIV Clinic via survey. Having less
than a high school education was associated with not having a Pap smear in the previous
year (Tello et al., 2010). Among the Swiss cohort study participants, having less
education, defined as less than completion of mandatory school, was a predictor of fewer
gynecologic examinations and Pap smears.
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Having less than a high school education was associated with lower Pap test
adherence in uninfected women (Bazargan et al., 2004; Coughlin, King, Richards, &
Ekwueme, 2006; Daley et al., 2011; Datta et al., 2006; Hewitt et al., 2004; Peterson et al.,
2008; Selvin & Brett, 2003), but another study concluded that education had no effect on
Pap test adherence (Blackwell et al., 2008). Twenty-one regional coordinators, health
care providers, and administrators in the state of Florida were interviewed about patient
barriers to cervical cancer screening, and they reported that low levels of education
prevented women from adhering to cervical cancer screening (Daley et al., 2011). Among
19,000 women living in the southeastern United States, 30% had less than a high school
education and 85% had not had a Pap test (Peterson et al., 2008). Having less than a high
school education was associated with low Pap test adherence in roughly 250,000 women
who participated in the Behavioral Risk Factor Surveillance System conducted between
2000 and 2002 (Coughlin et al., 2006). Having less than a high school education was
strongly associated with poor Pap test adherence in nearly 60,000 women in the Black
Women’s Health Study (Datta et al., 2006). Pap testing rates were lower in women with
less than a high school education in about 14,000 women of various ethnic backgrounds
from across the United States (Hewitt et al., 2004). The association between having a
lower level of education and poor Pap test compliance was statistically significant among
230 African American and Latino women living in three urban public housing
communities in Los Angeles (Bazargan et al., 2004). Women with a bachelor’s degree or
higher were 2.5 times more likely than women with less than a high school education to
report a recent Pap test, holding race/ethnicity constant (Selvin & Brett, 2003).
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Economics. Economic issues, such as a patient’s inability to pay for health
services due to lack of insurance or lack of financial resources, have been found to
contribute to patient reluctance to seek preventive care. In a study by Andrasik, Rose,
Pereira, and Antoni (2008), African American HIV-infected women, between the ages of
18 and 49 years and living in Miami, who had no history of a Pap test in the 5 years
before being interviewed, were asked questions to identify barriers to cervical cancer
screening. Seventy-seven percent of the women reported an annual income of less than
$10,000 and 80% reported being unemployed. Many of the women reported being
frustrated with their experiences while seeking medical care without insurance and
without the ability to pay for medications, services, gas, parking, or bus tickets to get to
appointment, all of which, consequently, created barriers to cervical cancer screenings
(Andrasik et al., 2008). A chart review of 200 women receiving care at a health
department in Florida revealed that women who had not received a Pap test in their first
year of HIV care were likely not to have had insurance (Logan, Khambaty, D’Souza, &
Menezes, 2010). One study disagreed with this trend, however. Stein and colleagues
(2001) used data from the HIV Cost and Service Utilization Study to examine the
sociodemographic, clinical, and provider factors associated with screening for cervical
cancer in HIV-infected women. The sample included 49,490 women from across the
United States. Income and insurance status were not associated with receiving a Pap test
(Stein et al., 2001). Data for uninfected women were mixed.
Many individuals cannot afford to pay for medical services, including Pap testing,
because of lack of insurance and the ability to pay. One article reported that insurance
had no effect on Pap testing among approximately 3,000 U.S. women participating in the
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2002-2003 Joint Canada/United States Survey of Health (Blackwell et al., 2008).
Although the data were mixed, most articles suggested that lack of insurance and inability
to pay for services decreased the odds of HIV-infected women having had a Pap test per
currently recommended guidelines (Bazargan et al., 2004; Daley et al., 2011; Hewitt et
al., 2004; Peterson et al., 2008; Warren, Londono, Wessel, & Warren, 2006).
Risky behaviors. Former and current drug use was associated with poor Pap test
adherence among 233 HIV-infected women receiving care at Boston Medical Center
(Baranoski et al., 2011). When limiting the study to African American women attending
the Johns Hopkins HIV Clinic, substance abuse was associated with not having a Pap
smear in the previous year (Tello et al., 2010). In chart reviews of 1,086 women attending
the Johns Hopkins HIV Clinic, Tello and colleagues (2008) revealed that illegal
substance use decreased the odds of a woman showing up for HIV-gynecological
appointments. Two hundred women attending a Florida county health department, who
reported participating in high risk behaviors such as injection drug use, were less likely to
have a documented Pap smear, but the association was not statistically significant (Logan
et al., 2010). Being a current intravenous drug user was associated with fewer Pap smears
in the Swiss cohort (Keiser et al., 2006). Women participating in a qualitative study in
Miami reported that more urgent needs, such as substance use, took priority over getting
screened for cervical cancer (Andrasik et al., 2008).
One study reported risky behavior as a barrier to cervical cancer screening in
uninfected women. Regional coordinators, health providers and administers in 10 rural
counties were interviewed regarding individual barriers to cervical cancer screening; they
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reported that behaviors such as drug use and having multiple sexual partners were
barriers (Daley et al., 2011).
HIV viral load. HIV viral load is the amount of virus in blood. Women with low
viral loads are usually more compliant with care guidelines. Women in the Swiss HIV
Cohort Study with viral loads lower than 400 copies/mL had had fewer Pap smears
(Keiser et al., 2006). Tello and colleagues (2008) did not find a statistically significant
association between viral load and Pap smear adherence but Tello and colleagues (2010)
reported that not having a Pap test in the previous year was associated with viral loads of
50 copies/mL or greater. A viral load of greater than 10,000 copies/mL was reported to
be associated with no Pap testing during an 18-month period (Baranoski et al., 2011).
CD4+ T lymphocyte count. Having a low (undetectable) CD4+ T lymphocyte
count or a CD4+ T lymphocyte count lower than 200 copies/mL were associated with no
Pap or poor Pap test adherence (Baranoski et al., 2011; Del Maso et al., 2010; Oster et al.,
2009; Rahangdale et al., 2010; Tello et al., 2008). Only one study did not find a
statistically significant relationship between lower CD4+ T lymphocyte counts and Pap
test adherence (Keiser et al., 2006).
Champion’s Health Belief Model Scale and Cervical Cancer
Several studies have used Champion’s Health Belief Model (CHBM) scale to
examine or predict factors associated with cervical cancer screening. This instruments
measures perceived susceptibility, perceived seriousness, perceived barriers and
perceived benefits. The research has been conducted in college women including nursing
students, lesbians, and women over the age of forty. Champion’s Health Belief Model
scale has been translated and used to assess women in Iran, Thailand, and Korea. The
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scale has not been used to assess women infected with HIV; therefore, the purposed
research added to the existing body of knowledge.
Perceived susceptibility.

Woman’s perception of their susceptibility to

cervical cancer varied. Ninety percent of Hispanic women participants felt that they were
susceptible to cervical cancer but susceptibility was not associated with previously
having a Pap test (Byrd, Peterson, Chavez & Heckert, 2004). In contrast, 209 Vietnamese
women living in Texas did not perceive that they were at risk for cervical cancer (Ho,
Yamal, Atkinson, Basen-Engquist, Tortolero-Luna & Follen, 2005). Seventy-nine percent
of the Vietnamese women were married which could contributed to their low perceived
risk of cervical cancer (Ho et al., 2005). A qualitative study involving, low-income
African American and Hispanic women age fifty and older believed that all women who
are sexually active are at risk for cervical cancer (Guilfoyle, Franco & Gorin, 2007).
More than 80% of female students at a New England college believed that they were very
unlikely to contract a sexually transmitted infection (STI) but only 40% believed that
they were unlikely or very unlikely to develop cervical cancer (Burak & Meyer, 1997).
About 70% of 189 Thai women believed they that would not develop cervical cancer or
were not at risk (Boonpongmanee & Jittanoon, 2007). Only one Thai woman reported
ever having a STI which could be the result of not being sexually, being educated or
using condoms more frequently. Mean perceived susceptibility subscale score were 17.4
for college aged women attending a large Midwestern university which could be the
result of high condom use, 66.7% of the participants having a Pap test with the past year
or 77% of the participants not being smokers (Ingledue et al., 2004). Similar results were
reported among 240 nursing students (Denny-Smith, Bairan & Page, 2006). Twenty-five
24

percent of women age forty to seventy believed that they were at risk for developing
cervical cancer which may be attributed to more than fifty percent of the participants
being married (Montgomery, Bloch, Bhattacharya & Montgomery, 2010).
In several studies, women who received Pap testing or intended to receive a Pap
test had a greater perception of susceptibility for developing cervical cancer than those
who had never had one or who had not had a pap test during the previous year (Ingledue,
Cottrell & Bernard, 2010; Tracy, Lydecker & Ireland, 2010; Ben-Natan & Adir, 2009;
Burak & Meyer, 1997). Despite higher scores for perceived susceptibility, many of the
findings were not statistically significant for women who were screened routinely and
those who were not (Ben-Natan & Adir, 2009; Montgomery, Bloch, Bhattacharya &
Montgomery, 2009; Boonpongmanee & Jittanoon, 2007; Denny-Smith et al., 2006; Park,
Chang & Chung, 2005; Burak & Meyer, 1997). In other studies there was no difference
between groups (Parks et al., 2005; Allahverdipour & Emami, 2008). There was not a
significant difference between women who had a Pap and women who did not but only
twenty-two percent of the women reported having had a Pap test (Ben-Natan & Adir,
2009). Of the 108 lesbians, only 30.8 percent intended to be tested within the year but
there was a significant difference between women who intended to be tested and women
who had no intentions of receiving a Pap test (Ben-Natan & Adir, 2009). The previous
study was conducted in Israelian women with 94.4% of the women reporting their
relationship status as single and the article failed to report the perceived susceptibility
scores (Ben-Natan & Adir, 2009). Among 225 lesbians in the Baltimore metro area,
women who were not screened routinely had a greater perception of being susceptible to
cervical cancer (Tracy et al., 2010). In many of the studies reviewed, perceived
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susceptibility was not a great predictor of Pap testing; contrary, to other studies,
knowledge and perceived susceptibility and severity were significant predictors of yearly
Pap test among 428 college women at a large Midwestern university, but perceived
susceptibility was not a good predictor alone (Ingledue et al., 2010). Boonpongmanee and
colleague (2007) reported perceived susceptibility as one of three predictor of Pap
testing.
Perceived seriousness. Some women seem to understand the seriousness of
cervical cancer (Byrd et al., 2004; Burak & Meyer, 1997), but in several studies
differences between groups (Pap vs. no Pap and intenders vs. non-intenders) were not
significant, if a difference exist (Montgomery et al., 2010; Tracy et al., 2010; Ben-Natan
& Adir, 2009; Boonpongmanee & Jittanoon, 2007; Denny-Smith et al., 2005; Park et al.,
2005; Burak & Meyer, 2005: Byrd et al., 2004). Perceived seriousness (severity) scores
were low ranging for 17 to 24 out of a possible 45 (Montgomery et al., 2010; Ho et al.,
2009; Allahverdipour & Emami, 2008; Denny-Smith et al., 2005; Ingledue et al., 2004).
Only two percent (4/206) Vietnamese women believed that cervical cancer is serious but
the translations ask that women if they were afraid of cervical cancer which does not
mean seriousness (Ho et al., 2005). Among college student at a large Midwestern
university perceived seriousness was negatively correlated with knowledge (Ingledue et
al., 2004) but in a similar study in college students at a large southeastern university, the
inverse relationship was not significant. The southeastern study was conducted in nursing
student who may have more knowledge about HPV and cervical cancer, but most the
college women did not believe that cervical cancer was serious. In a study among
women forty to seventy years of age using the same questionnaire as the previously
26

reported studies, found a positive relationship between knowledge and perceived
seriousness but the internal consistency was low (α =0.20).
Contrary to previously reported studies, perceived seriousness differed between
woman who had had a Pap over the past year, women who had had a Pap but not over the
past year and women had never had a Pap (Ingledue et al., 2004). Non-routine, lesbian
Pap screeners had a greater perception that cervical cancer was serious but their scores
did not differ significantly from routine screeners (Tracy et al., 2010). Perceived
seriousness scores were higher among the 225 self-identified lesbians than other studies,
greater than thirty out of a possible forty-five (Tracy et al. 2010). Perceived seriousness
does not appear to be a good predictor of cervical cancer screening.
Perceived barriers. Perceived barriers and benefits appear to be significant
predictive variables related to Pap testing and risk behaviors such as condom use and
number of sexual partners. It is difficult to separate the two variables, but we explained
the literature regarding the two variables in separate paragraphs. Women who had a
history of a previous Pap test perceived fewer barriers than those who did not report a
history of a previous Pap test (Allahverdipour & Emami, 2008). Perceived barriers were
cited as a significant predictor of having had a Pap test (Tracy et al., 2010;
Allahverdipour & Emami, 2008; Lee et al., 2008; Boonpongmanee & Jittanoon, 2007; Ho
et al., 2005). Procedural and cognitive barriers including feelings of embarrassment and
shame and worrying about results were significantly less in the forty women in the
experimental group (Park et al., 2005). Similarly, Park and colleagues reported fear of
pain and embarrassment, partner disapproval and not knowing where to obtain a Pap test
as factors associated with never having had a Pap test (Byrd et al., 2004).
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Boonpongmanee and Jittanoon (2007) also reported embarrassment, fear and knowing
where to obtain a Pap test as perceived barriers; in addition to, forgetting, being too busy
and the cost of the test. The experimental group received one-one hour session which
provided information about cervical cancer and Pap smear. Perceived barriers were a
predictor for Pap testing in a Thailand study of 189 women ages twenty-five to fifty-five
(Boonpangmanee & Jittanoon 2007).
Two qualitative studies reported barriers to Pap testing. Korean women in South
Korea reported the following barriers: cost, lack of insurance, lack of time, language
difficulties, fatalistic attitudes, embarrassment, lack of knowledge and being
asymptomatic (Lee, 2000). Seven years later a similar study was conducted in New York
in older women who reported the same barriers (Guilfoyle et al., 2007). Additionally, the
researchers reported having a previous negative experience with a provider as a barrier.
For example: providers not communicating results and having unnecessary exploratory
procedures (Guilfoyle et al., 2007).
Perceived benefits. Women who had Pap tests were more likely to have the
perception that the benefits outweighed the barriers (Tracy et al., 2010; Lee et al., 2008;
Boonpangmanee & Jittanoon 2007; Ho et al., 2005; Burak & Meyer, 1997). Women who
participated in an intervention aimed at increasing knowledge about cervical cancer and
Pap test reported more benefits (Park et al., 2005). Four hundred undergraduate female
students at a New England state college completed a survey and 104 reported that they
had no intention of getting a Pap smear while 226 reported that they had not had one in
the past six months but would be getting a Pap smear during the current year. The women
who intended to get a Pap smear perceived more benefits than barriers and felt more
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susceptible to developing HPV (Burak & Meyer, 1997). Likewise in a study among
Korean women living in California, those who believed they had fewer benefits and more
barriers had decreased odds of having had a Pap test (Lee, Fogg, Menon, 2008). In a
study among young Hispanic women perceived benefits were not associated with having
a pervious Pap test (Byrd et al., 2004). More benefits and fewer barriers were better
predictors of having had a Pap test (Boonpangmanee & Jittanoon 2007; Burak & Meyer,
1997).
Knowledge
Two studies with the purpose of assessing knowledge of, perceived susceptibility
to, perceived seriousness of and risk behaviors regarding HPV and cervical cancer were
conducted in female college students, specifically nursing students in the first study. Both
found no significant relationship between HPV/cervical cancer knowledge and perceived
susceptibility (Denny-Smith, Bairan & Page, 2006; Ingledue, Cottrell & Bernard, 2004)
but the two studies differed in its findings regarding the relationship between knowledge
and seriousness. Among 240 bachelor’s degrees seeking nursing students a significant
positive relationship was not found between HPV/cervical cancer knowledge and
perceived seriousness (Denny-Smith, Bairan & Page, 2006). Oddly, among 428
traditional student attending a large Midwestern university, a significant negative
correlation was found between HPV/cervical cancer knowledge and perceived
seriousness (Ingledue et al., 2004). The significant finding may be attributed to low levels
of knowledge regarding HPV/cervical cancer, mean knowledge score 6.8/15 (Ingledue et
al., 2004). Another study with the same purpose and utilizing the same instrument was
conducted in women between the ages of forty and seventy found little to no relationship
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between knowledge, perceived seriousness and perceived susceptibility (Montgomery,
Bloch, Bhattacharya & Montgomery, 2010).
Knowledge was associated with Pap test adherence. Women who were more
knowledge about cervical cancer were more likely to have had a Pap smear during a
twelve month period (Ingledue et al., 2004). Women who knew that Pap test could detect
cervical cancer early were five times more likely to have had a Pap test than women who
were not knowledgeable (Lee at al., 2008). Three hundred and thirty-three Iranian women
were surveyed using CHBM scale to assess for associations between HBM variables and
participation in cervical cancer screenings. Pap test knowledge increased as perceived
benefits to early detection increased and perceived susceptibility to cervical cancer
increased (Allahverdipour & Emami, 2010).
Summary
The human papillomavirus (HPV) is a group of viruses that are sexually
transmitted and if left undetected or untreated can lead to cancer. The most common
cause of cervical cancer is HPV. Women infected with HIV are at an increased risk of
acquiring HPV and developing cervical cancer. Cervical cancer screening guidelines for
HIV-infected women require Pap testing more frequently. Many HIV-infected women do
not adhere to cervical cancer screening regardless of the current ACOG guidelines. A
review of literature has uncovered many cited factors that are barriers to cervical cancer
screening in women and more specifically HIV-infected women. These barriers include
older age, ethnicity/race, weight, tobacco use, level of education, economics, risky sexual
behavior, high HIV viral load and low CD4+ T lymphocyte count.
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The studies found pertinent information that could be the foundation for future
interventions domestically and internationally and in various women from lesbians to
married women to college women involved in risky sexual behavior. The proposed study
was critical because the population being evaluated consists of women who are at a
greater risk for developing cervical dysplasia and cervical cancer secondary to being
immune compromised and having a history of being involved indirectly or directly in
risky sexual behavior. Further, this study measured perceived self-efficacy to cervical
cancer screening using CSE scale: therefore, making this aspect of the proposed study
unique.
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Chapter Three: Method

The methods section describes the research design, the study participants,
sampling procedure, sample size, measures used for data collection, procedure for
collecting data and method of data analysis. Figure 1 illustrated a conceptual model of the
concepts evaluated in the study.
Design
The study is an exploratory, cross-sectional, quantitative correlational design. A
correlational design was selected because the researcher is exploring relationships among
variables. The dependent or outcome variable is adherence to cervical cancer screening
using Pap testing. The design allowed the researcher to predict the outcome variable
using multiple independent variables.
Population/Setting
Participants were recruited from the waiting rooms of two health department’s
HIV ambulatory care center located in central Florida. The clinics were selected because
they served patients infected with HIV and Acquired Immune deficiency Syndrome
(AIDS). The clinic serves more than 1,000 patients annually, of whom, about 400 are
women. The reported cases of HIV from 1983 to June 2011 by race/ethnicity for the rural
county are as follows: 56% were Black/African American women, 31% were White, 11%
were Hispanic (all races), one percent was identified as multi-race and less than one
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percent was identified as American Indian/Native American or Native Hawaiian/Pacific
Islander. The clinic is staffed with one medical doctor and two advanced registered nurse
practitioners (ARNP). The specialties of the medical doctor include: internal medicine,
pediatrics, and infectious disease. The specialties of the ARNPs include: family health,
adult health and infectious disease.
Sample
A convenience sample drawn from the patient population at the study site was
used. Inclusion criteria were as follows: the participants must be women, 18 years of age
or older, and patients of the clinic to participate. Women with a history of having had a
hysterectomy and women who cannot read and comprehend the English language were
excluded from the study. Each woman received a $15 Walmart gift card as compensation
for her time.
Power analysis was conducted for Pearson’s r using a small (0.2) effect size
assuming power = .80 and α = .05. The analysis indicated that the sample size needed
was 192. Also a power analysis was conducted using an effect size of (0.3) assuming
power = .8 and α = .05 and the sample size needed was 83. For analysis of variance
(ANOVA) assuming power = .80 and α = .05, the sample size needed for a medium
effect (0.5) was 64 women in each group for a total of 128 women. A power analysis for
multiple logistic regression using a tolerance of .60, assuming power = .80 and α = .05
and a assuming an odds ratio of at least two indicated a sample of size of 276. Although
the power analysis for multiple regression indicated sample size of 276, the desired
sample size for the study was n=300. Over sampling by 24 participants was done to
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account for missing data in the event that a small percentage of the participants elected
not to answer every question.
Instruments
Six scales, one demographic questionnaire, four questions and one chart review
questionnaire were used in the proposed study. The scales are described in the following
paragraphs.
Demographic questionnaire. The demographic questionnaire was developed by
the researcher. The questionnaire included 20 questions regarding age (not date of birth),
race/ethnicity, marital status, primary language, education level, CD4+ T lymphocyte
count, HIV viral load, hysterectomy history, height, weight, cigarette use, substance use,
Pap test history, number of sexual partners, condom use and year of HIV diagnosis. The
demographic questionnaire was done in two parts: part one was a medical record review
completed by the primary investigator and part two was completed by the participant.
The questions were selected based on the review of related literature.
Champion’s Health Belief Model scale. Perceived susceptibility, perceived
seriousness (severity), perceived benefits, and perceived barriers were measured using an
adapted version of Champion’s Health Belief Model (CHBM) (1984) scale for cervical
cancer and Pap test. Champion’s Health Belief Model scale consists of four sub-scales.
The four sub-scales, totaling 28-items, are measured with a 5-point Likert-like scale
ranging from strongly agree to strongly disagree (Guvenc et al., 2011; Champion, 1998).
Reported internal consistency for perceived susceptibility, seriousness and barriers is .70
and above (Guvenc et al., 2011; Medna-Shepherd & Kleier, 2010; Champion, 1984).
Internal consistency for perceived benefits varied ranging from .62 to .80 (Guvenc et al.,
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2011; Medna-Shepherd & Kleier, 2010; Champion, 1999, Champion, 1984). Test-retest
reliability coefficients for the perceived benefits, barriers, seriousness and susceptibility
have ranged from .65 to .88 (Guvenc et al., 2011; Medna-Shepherd & Kleier, 2010;
Champion, 1999, Champion, 1984). Construct validity for perceived benefits, barriers,
seriousness and susceptibility was examined by factor analysis and most of the items
loaded on their perspective factors at .35 and above (Guvenc et al., 2011; MednaShepherd & Kleier, 2010; Champion, 1999, Champion, 1984).
Champion’s self-efficacy scale. Self-efficacy (confidence) were measured using
Champion’s Self-Efficacy (CSE) (2005) scale, which consisted of ten questions. The
scale is measured with a 5-point Likert-like scale ranging from strongly agree to strongly
disagree (Champion, Skinner & Menon, 2005). The CSE scale has not been widely
utilized in research. The scale has a Cronbach’s alpha of .87 and a Pearson’s coefficient
of .52 for test-retest reliability.
HPV/Cervical cancer knowledge. Human papillomavirus and cervical cancer
knowledge was measured by fifteen-multiple choice questions. The questionnaire was
developed by Ingledue and colleagues (2004). The original scale consisted of 40-items
measuring HPV and cervical cancer knowledge, perception and preventive behaviors. For
the purposes of this study, the first 15-items measuring HPV and cervical cancer was
used. Each question has one correct response. The possible range of scores is from zero
to fifteen and higher scores equate to more knowledge (Denny-Smith et al., 2006;
Ingledue et al., 2004). Content validity for the knowledge portion of the test was
determined by a panel consisting of two gynecologists, two professors of health
education, and a medical professional from the Breast and Cervical Program (Ingledue et
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al., 2004). Test-retest reliability for knowledge was .90 (Ingledue et al., 2004). Internal
consistency for the knowledge scale was not reported.
Cues to action. Cues to action was evaluated with one question, developed by the
researcher. The question assessed triggers that encouraged women to get a Pap smear.
Data Collection
Data collection began after the study was approved by the Florida Department of
Health’s Institutional Review Board (IRB) (Appendix A). Participants were recruited
from the waiting room of a local health department’s HIV ambulatory care clinic. To
reduce the risk of identifying the participants, the researcher requested a waiver of
documentation of consent because the consent form would be the only document
identifying the patient by name. Each participant was given an informed consent cover
letter, a survey and an envelope. The informed consent cover letter informed the
participants that their involvement was voluntary and would not influence the care they
received (Appendix B). The participant implied consent to the study by completing the
survey. Each survey was assigned a unique identifier. The unique identifier was written
on the top of both surveys. The unique identifier allowed the researcher to match the
participant’s completed survey to the chart review questionnaire.
Data collection occurred in two phases. Phase one consisted of a self-administered
survey completed by the participant (Appendix C). The survey could be completed in 45
minutes or less. Phase two consisted of a review of the participant's chart by the
researcher (Appendix D). The chart review was completed while the participant was
completing the self-administered survey. After completing the questionnaire, the
participant showed the survey to the researcher who reviewed it for completeness. If the
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questionnaire was not complete, the participant was given an opportunity to answer any
incomplete questions. At that time, the researcher gave the participant a $15 Walmart gift
card as compensation for her time. The surveys was placed in an envelope and locked in
a secure office in a locked cabinet. In addition, completed surveys were scanned and
saved to a password-protected flash drive. The original documents were shredded after
the documents are scanned. The data will be maintained for 5 years as per DOH IRB
policy.
Data Analysis
The data were analyzed using SPSS statistical software (Version 21). Descriptive
statistics were used to describe sample characteristics and Pap smear adherence. Means
and standard deviations were calculated for perceived susceptibility, seriousness, barriers,
benefits and self-efficacy, in addition to HPV and cervical cancer knowledge. Pearson’s
correlation coefficients were calculated to assess the relationship within the HBM
variables and between the demographic. Analysis of variance (ANOVA) was used to
determine whether mean differences exist for perceived susceptibility, seriousness,
barriers, benefits and self-efficacy and knowledge between women who report having
had a Pap test during the past year and women reporting not having had a Pap test during
the past year. Multiple logistic regression was used to determine whether the perceived
susceptibility, seriousness, barriers, benefits, self-efficacy and knowledge predict cervical
cancer screening adherence. Also multiple logistic regression was used to determine
whether age, race/ethnicity/ marital status, primary language, education level, CD4+ T
lymphocyte count, HIV viral load, BMI, tobacco use, substance use, history of abnormal
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Pap test, number of sexual partners, condom use and year of HIV diagnosis are predictors
of cervical cancer adherence.
Summary
The proposed study was an exploratory, cross-sectional, quantitative correlational
design with the purpose of evaluating HIV-infected women’s knowledge of and
perceived susceptibility to cervical cancer, and their perceived seriousness of developing
cervical cancer, as well as assessing their perceived self-efficacy, benefits, and barriers
and health motivation to cervical cancer screening. In addition, the relationship between
select demographic factors and cervical cancer screening were evaluated. The women
were recruited from two specialty care clinics in central Florida. The sample was one of
convenience with the expectation of having a sample of 300. The following instruments
were used: CHBM and CSE scales and HPV/cervical cancer knowledge scale by Dr.
Sandmaire. The validity and reliability of the previously stated instruments were assessed
in published articles. The participants were given a questionnaire with a consent form.
The researcher collected the consent form, which contained the patient’s unique
identifier. The researcher reviewed the questionnaire for completeness and the participant
placed the questionnaire in an envelope. After completing the questionnaire, a $15
Walmart gift card was given. Then, the data was analyzed using SPSS version 21.

38

Chapter Four: Results

The purpose of this study was to evaluate HIV-infected women’s knowledge of
and perceived susceptibility to cervical cancer, and their perception of the seriousness of
developing cervical cancer, as well as assessing their perceived self-efficacy, benefits,
and barriers to cervical cancer screening. In addition, predictors of cervical cancer
screening in HIV-infected women were evaluated. Chapter four presents the results from
the pencil and paper survey, which consisted of a participant survey and chart review
survey. The chapter results are presented in five sections. Section one presents descriptive
statistics of health-related behaviors, socio-demographic, clinical and subscale variables.
Section two presents data related to the relationships between Pap test adherence
(participant reported and chart review), and the following subscales: CHBM, CSE and
HPV knowledge using ANOVA. In section three, the relationships between the following
subscale variables: CHBM, CSE and HPV knowledge scales, and select demographic
variables using ANOVA and Pearson’s correlations are presented. Multiple logistic
regression results between Pap test adherence (participant reported and chart review) and
potential predictor variables are presented in section four. Section five presents
Cronbach’s alpha values to evaluate internal consistency of study instruments. In
addition, the relationship between sources of last Pap smear reported and the relationship
between sources of having a history of an abnormal Pap smear.
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Sample Characteristics
The sample consisted of 300 participants, who were recruited from two (one rural
and the other metropolitan) ambulatory HIV care clinics in Florida. The majority of
participants were Black (70.3%). Ethnicity was categorized as African American (68%),
Hispanic-Latina (14%), Caucasian (16.3%), and other (1.7%). The majority of
participants had at least a high school education (Table 1).
Table 1. Frequency and Percent of Participants by Sociodemographic Variables.
Variables
Frequency
Percent
Race
Black
211
70.3
White
89
29.7
Ethnicity
African American
204
68.0
White (non-Hispanic)
49
16.3
Hispanic/Latina
42
14.0
Other
5
1.7
Education
Less than high school
99
33.0
High school/trade school
151
50.3
College
50
16.7
Primary Language
English
260
86.7
Spanish
24
8.0
Creole
15
5.0
Other
1
0.3
Marital status
Single
163
54.3
Divorced
50
16.7
Married
48
16.0
Significant other
22
7.3
Widowed
17
5.7
Note. n = 300.
Approximately 50% of the women reported smoking cigarettes. The majority of
the participants denied a history of current or past substance use. About half of the
women reported being sexual activity with one partner. The majority of women reported
using condoms at least 75% of the time (Table 2).
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Table 2. Frequency and Percent of Participants by Risky Behavior Variables.
Variables
Frequency
a
Cigarette use
No
152
Yes
148
Currently
106
Formerly
42
a
Substance use
No
242
Yes
58
Currently
7
Formerly
53
Condom usea
Never
42
25%
11
50%
13
75%
29
100%
165
I don’t want to answer
40
Number of sex partnersa
0
96
1
161
2 or more
29
I don’t want to answer
14
b
Sexual activity
Currently active
151
Not active
142
Never
6
Missing
1
a
b
Note: n = 300, n = 299.

Percent
50.7
49.3
71.6
28.4
80.7
19.3
11.7
88.3
14.0
3.7
4.3
9.7
55.0
13.3
32.0
53.7
9.7
4.7
50.3
47.3
2.0
0.4

All of the women had a diagnosis of HIV, but 48.4% of the women had an AIDS
diagnosis. A review of medical charts revealed that less than half of the women were
diagnosed with depression. The majority of women reported having a Pap smear during
the past year. However, a review of their medical charts revealed that approximately 56%
of the women had not had a Pap smear during the past year. Approximately half of the
women reported not having a history of an abnormal Pap smear, and the medical chart
revealed similar results (Table 3).
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Table 3. Frequency and Percent of Participants by Clinical Variables.
Variables
Frequency
Percent
Medical chart review
Last Pap smeara
< 1 year
131
43.7
> 1 year
169
56.3
History of abnormal Papc
Yes
115
38.3
No
169
56.3
Missing
16
5.4
a
History of depression
Yes
129
43.0
No
171
57.0
Diagnosisa
HIV
155
51.7
AIDS
145
48.3
Participant-reported
Last Pap smeara
< 1 year
224
74.7
> 1 year
76
25.3
History of abnormal Papb
Yes
150
50.2
No
149
49.8
a
b
c
Note: n = 300, n = 299, n = 284.
The participants’ ages ranged from 18 to 70 years old, with a mean age of 45.36
(SD=11) (Table 4). 35.5 % of the women were 50 years old, 7.7% of women were 60
years of age or greater and 10% were 29 years of age or younger. Eighty percent of
women were recruited from a metropolitan HIV ambulatory clinic and 20% from a rural
HIV ambulatory clinic.
Perceived susceptibility measured women’s perceived susceptibility to cervical
cancer, and perceived susceptibility scores were low. Perceived seriousness included
seven questions that were used to measure women’s perception of the severity of cervical
cancer. In general, women perceived that Pap smears were beneficial (M = 15.93).
Champion’s perceived barriers subscale measured women’s perceived barriers to
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obtaining a Pap smear, and scores were low (M = 29.26). HPV/cervical cancer
knowledge scores were low with a mean of 6.02. Height and weight were collected for
each participant, and used to calculate BMI. Ideal BMI range is 18.5 – 24.9, and overall
the women in this study were overweight (M = 29.25) (Table 4).
Table 4. Means and Standard Deviation for Subscales, Age and BMI for all Participants.
Variables
Range
Mean
Standard Deviation
Age
18 - 70
45.36
11.00
Perceived Susceptibility
4 - 20
9.59
4.06
Perceived Benefits
4 - 20
15.93
3.20
Perceived Seriousness
7 - 35
20.88
6.12
Perceived Self-efficacy
10 - 50
40.22
6.98
Perceived Barriers
14 -56
29.16
9.09
BMI
15 - 55.91
29.25
7.85
Knowledge
0 - 14
6.02
3.59
Note: n=300.
Aim One
Aim one was to evaluate the relationships between Pap test adherence in women
infected with HIV and the following variables: a) CHBM scales, b) CSE scale, and c)
HPV/cervical cancer knowledge scale. Outcome variables were created from two
questions on the questionnaire: participant reported last Pap smear was categorized as
either had a Pap during the past year or no Pap smear, and medical chart review last Pap
smear was separated into either had a Pap during the past year or no Pap smear.
Participant reported Pap smear. A one-way ANOVA was used to examine
differences in subscale variables by participant reported Pap smear. There were
differences between the following subscale variables (knowledge, susceptibility,
seriousness and benefits) and participant reported Pap smear, but the differences were not
statistically significant. Differences in perceived barriers (p >.001; ƞ2 = .016) and self43

efficacy (p = .029; ƞ2 = .051) by Pap smear adherence were statistically significant.
Women who reported a Pap smear during the past year had higher perceived self-efficacy
scores and lower perceived barrier scores than women who reported having a Pap smear
greater than one year ago (Table 5).
Table 5. Differences in Subscale Scores by Participant Reported Pap Smear.
Pap
M
SD
F
df
p
a
Knowledge
<1year 5.89
3.74
b
1.11
(1,298)
.293
>1year 6.39
3.08

.004

Susceptibility <1yeara
>1yearb

ƞ2

9.65
9.38

4.23
3.51

0.26

(1,298)

.611

.001

<1yeara
>1yearb

20.63
21.59

6.37
5.28

1.40

(1,298)

.239

.005

<1yeara
>1yearb

16.05
15.55

3.23
3.07

1.40

(1,298)

.239

.005

<1yeara
>1yearb

27.96
32.67

9.01
8.46

15.95

(1,298)

.000

.051

<1yeara
>1yearb
a
Note. n = 224, nb = 76.

40.73
38.71

7.32
5.60

4.83

(1,298)

.029

.016

Seriousness

Benefits

Barriers

Self-efficacy

Medical chart documented Pap smear. ANOVA (one-way) was used to
determine differences in subscale variables by medical chart documented Pap smear. The
analysis revealed that differences in subscale variables by medical chart documented Pap
smear were small. The relationships between medical chart-documented last Pap smear
and the subscale variables were not statistically significant (Table 6).
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Table 6. Differences in Subscale Scores by Medical Chart Reported Pap Smear.
Pap
M
SD
F
df
p
Knowledge
<1yeara 6.11
3.60
0.16
(1,298)
.689
>1yearb 5.95
3.59

.001

Susceptibility <1yeara
>1yearb
Seriousness

Benefits

Barriers

ƞ2

9.66
9.53

4.28
3.89

0.08

(1,298)

.772

.000

<1yeara
>1yearb

20.95
20.82

6.28
6.02

0.04

(1,298)

.847

.000

<1yeara
>1yearb

15.79
16.03

3.54
2.91

0.40

(1,298)

.527

.001

<1yeara
>1yearb

29.70
28.45

9.22
8.93

1.404

(1,298)

.237

.005

0.06

(1,298)

.801

.000

<1yeara 40.33
7.86
>1yearb 40.13
6.23
a
b
Note. n= 131, n = 169, Total n = 300.
Self-efficacy

Aim Two
Aim two was to evaluate relationships among the subscales (CHBM, CSE, and
knowledge scales) and select demographic variables in HIV-infected women. Pearson’s
correlation was used to evaluate the relationship between continuous variables. ANOVA
was used to assess the relationship between a continuous and a categorical variable.
Sociodemographic. The associations between the subscale variables and the
following sociodemographic variables are presented: race, education, marital status, and
language. No statistically significant relationships were revealed between the subscale
variables (CHBM, CSE, and HPV knowledge) and marital status (Table 7). Statistically
significant relationships were found between subscale variables and the following
variables: race, education and language.
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Table 7. Differences in Subscale Scores by Marital Status.
Marital
M
SD
F
df
Status
Knowledge
Singlea
5.98
3.47
2.02
(4, 295)
Significant 7.68
3.06
otherb
Marriedc
6.08
4.13
d
Divorced
5.92
3.54
e
Widowed
4.47
3.47
Susceptibility Singlea
Significant
otherb
Marriedc
Divorcedd
Widowede

4.30
3.48
4.81

Singlea
Significant
otherb
Marriedc
Divorcedd
Widowede

20.63
19.82

6.22
4.92

21.96
21.48
19.77

5.48
6.17
7.98

Singlea
Significant
otherb
Marriedc
Divorcedd
Widowede

15.83
16.68

3.46
2.64

16.25
15.96
14.82

2.94
2.79
2.94

Singlea
Significant
otherb
Marriedc
Divorcedd
Widowede

30.00
29.77

9.78
7.57

28.88
26.70
28.35

8.01
8.37
8.51

.03

.59

.01

0.86

(4, 295)

.49

.01

0.97

(4, 295)

.42

.01

1.33

(4, 295)

.26

.02

Singlea
39.50 7.11
1.09
(4, 295)
Significant 40.36 5.31
otherb
Marriedc
41.58 7.55
d
Divorced
41.04 6.13
Widowede
40.71 8.07
a
b
c
Note. n = 163, n = 22, n = 48, nd = 50, ne = 17, Total n = 300.

.36

.02

Barriers

10.46
9.58
9.12

.09

(4, 295)

Benefits

4.03
4.48

ƞ2

0.70

Seriousness

9.39
9.50

p

Self-efficacy
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Race and language. Using ANOVA, statistically significant relationships were
found between perceived susceptibility and race, and perceived self-efficacy and primary
language spoken. White women perceived themselves to be more susceptible than black
women to cervical cancer (p <.001) (Table 8). Using Tukey’s HSD (honestly significant
difference) post hoc test, pairwise differences were revealed. Women who spoke English
had higher self-efficacy scores than women who spoke Spanish (p = .035) (Table 9).
Table 8. Differences in Subscale Scores by Race.
Knowledge

Race
Blacka
Whiteb

M
5.88
6.36

SD
3.58
3.61

F
1.11

df
(1, 298)

p
.29

ƞ2
.00

Susceptibility

Blacka
Whiteb

8.98
11.03

3.94
3.98

16.94

(1, 298)

<.001

.05

Seriousness

Blacka
Whiteb

20.76
21.16

6.48
5.22

0.27

(1, 298)

.60

.00

Benefits

Blacka
Whiteb

16.12
15.46

3.28
3.00

2.70

(1, 298)

.10

.01

Barriers

Blacka
Whiteb

28.64
30.39

9.32
8.47

2.35

(1, 298)

.13

.01

7.22
6.38

0.68

(1, 298)

.41

.00

Blacka
40.44
b
White
39.71
Note. na = 211, nb = 89. Total n = 300.
Self-efficacy

Education. Using ANOVA, statistically significant differences exist in
knowledge, and perceived benefits, barriers and self-efficacy by education. Using
Tukey’s HSD post hoc test, women with less than a high school education had lower
perceived self-efficacy scores than women with a high school diploma (p = .019), and
women with a college education (p = .002). Women with less than a high school
education perceived more barriers than women with a college education (p =.014).
Women with less than a high school education perceived fewer benefits to Pap testing
47

than women with a high school diploma (p < .001), and women with a college education
(p = .001). Women with a college education had higher knowledge scores than women
with less than a high school education (p <.001) and women with a high school education
(p =.012) (Table 10).
Table 9. Differences in Subscale Scores by Primary Language Spoken.
Language
M
SD
F
df
p
a
Knowledge
English
6.10
3.60
0.53
(2, 296)
.59
Creoleb
5.80
3.65
Spanishc
5.33
3.60

ƞ2
.00

Susceptibility

Englisha
Creoleb
Spanishc

9.42
9.40
11.38

4.06
4.07
3.85

2.58

(2, 296)

.08

.02

Seriousness

Englisha
Creoleb
Spanishc

20.87
20.67
20.92

6.20
5.58
5.90

0.00

(2, 296)

.99

.00

Benefits

Englisha
Creoleb
Spanishc

16.00
15.20
15.38

3.02
5.05
3.65

0.83

(2, 296)

.44

.01

Barriers

Englisha
Creoleb
Spanishc

28.65
31.47
32.88

8.75
11.20
10.70

2.23

(2, 296)

.06

.02

Englisha
40.67 6.57
3.90
Creoleb
38.07 10.35
Spanishc
37.00 7.92
a
Note. n = 260, nb = 15, nc = 24, Total n = 299.

(2, 296)

.02

.03

Self-efficacy

Age. Bivariate correlations were computed to determine if an association exists
between the subscale variables and age. A statistically significant weak, negative
correlation exists between HPV knowledge and age; therefore, as age increases
knowledge decreases (r = -.292, p < .001). Statistically significant relationships were
revealed between perceived susceptibility and age (r = -.140, p = .015) and perceived
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self-efficacy and age (r = -.155, p = .007). As age increases perceived susceptibility and
self-efficacy decreases (Table 21).
Table 10. Differences in Subscale Scores by Education.
Education
< High schoola
High schoolb
Collegec

M
5.22
6.01
7.66

SD
3.26
3.50
3.98

F
8.02

df
(2, 297)

p
<.001

ƞ2
.05

Susceptibility

< High schoola
High schoolb
Collegec

9.99
9.36
9.46

4.08
4.02
4.14

0.74

(2, 297)

.48

.01

Seriousness

< High schoola
High schoolb
Collegec

21.57
20.64
20.24

6.36
6.10
5.68

1.01

(2, 297)

.36

.01

Benefits

< High schoola
High schoolb
Collegec

14.71
16.46
16.74

3.58
2.89
2.57

11.68

(2, 297)

<.001

.07

Barriers

< High schoola
High schoolb
Collegec

30.86
28.94
26.44

9.80
8.70
8.24

4.09

(2, 297)

.02

.03

< High schoola
38.32
7.42
High schoolb
40.73
6.36
Collegec
42.44
7.08
a
b
c
Note. n = 99, n = 151, n = 50, Total n = 300.

6.85

(2, 297)

<.001

.04

Knowledge

Self-efficacy

Risky behavior. For the purpose of this study risky behaviors consist of the
following variables: cigarette use, substance use, condom use, number of sexual partners,
and sexual experience or activity. This section presents data about statistically significant
relationships between the subscale variables and the risky behavior variables. No
statistically significant relationship was revealed between the subscales variables
(CHBM, CSE, and HPV knowledge) and substance use (Table 11).
Cigarette use. The relationship between perceived susceptibility and cigarette use
was statistically significant. Although not statistically significant, women who reported a
history of cigarette use felt that cervical cancer was more serious, and they were more
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knowledgeable about cervical cancer and HPV. The women were less confident in
requesting a Pap smear, and they felt that there were more benefits and fewer barriers to
screening than women without a history of cigarette use (Table 12).
Table 11. Differences in Subscale Scores by Substance Use.
F

df

p

ƞ2

3.06
3.71

0.64

(1, 298)

.43

.00

10.26
9.43

3.89
4.09

1.98

(1, 298)

.16

.01

Yesa
Nob

21.62
20.70

4.83
6.39

1.06

(1, 298)

.30

.00

Benefits

Yesa
Nob

15.78
15.96

2.33
3.37

0.16

(1, 298)

.69

.00

Barriers

Yesa
Nob

30.36
28.87

9.29
9.05

1.26

(1, 298)

.26

.00

Yesa
38.69
Nob
40.59
Note. na = 242, nb = 58, Total n = 300.

5.95
7.16

3.49

(1, 298)

.06

.01

Substance
use
Yesa
Nob

M

SD

6.36
5.94

Susceptibility

Yesa
Nob

Seriousness

Knowledge

Self-efficacy

Table 12. Differences in Subscale Scores by Cigarette Use.
F

df

p

ƞ2

3.59
3.79

0.19

(1, 298)

.66

.00

10.12
9.08

4.25
3.81

4.88

(1, 298)

.03

.02

Yesa
Nob

21.27
20.49

5.97
6.27

1.21

(1, 298)

.27

.00

Benefits

Yesa
Nob

15.92
15.93

2.96
3.42

0.00

(1, 298)

.97

.00

Barriers

Yesa
Nob

29.22
29.10

8.65
9.54

0.01

(1, 298)

.91

.00

Yesa
39.94
Nob
40.49
Note. na = 148, nb = 152, Total n = 300.

6.67
7.28

0.47

(1, 298)

.49

.00

Cigarette
use
Yesa
Nob

M

SD

6.11
5.93

Susceptibility

Yesa
Nob

Seriousness

Knowledge

Self-efficacy
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Condom use. A statistically significant difference in perceived barriers and HPV
knowledge existed across levels of condom use (p = .035, ƞ2 = .04; p =.046, ƞ2 = .038,
respectively). No statistically significant pairwise differences were revealed for perceived
barriers using post hoc testing. Tukey’s HSD post hoc test revealed a statistically
significant relationship in HPV knowledge between women who reports using condoms
75% of the times in comparison to women who did not want to report their condom usage
(p =.027). It should be noted that women who reported using condoms 75% of the time
had the highest mean knowledge scores (Table 13).
Number of sex partners. A statistically significant differences were found
between perceived self-efficacy and HPV knowledge by of number of sexual partners (p
=.047, ƞ2= .027; p =.027, ƞ2= .030). Post hoc testing for perceived self-efficacy did not
reveal any statistically significant pairwise differences. Tukey’s post hoc test revealed
that women who reported not having any sexual partners during the past 12 months had
lower knowledge scores than women who reported having two or more partners during
the past year (Table 14).
Sexual experience. Statistically significant relationships exist between sexual
experience and specific subscale variables (perceived self-efficacy and HPV knowledge).
Using Tukey’s HSD post hoc test, women who reported no sexual activity during the past
12 months had higher perceived self-efficacy scores than women who reported having
sex during the past 12 months (p <.001). Women who reported having sex during the past
12 months had higher self-efficacy scores than women who reported never having sexual
intercourse (p <.001). Women who reported no sexual activity during the past 12 months
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had higher knowledge scores than women who reported never having sexual intercourse
(p = .032) (Table 15).
Table 13. Differences in Subscale Scores by Condom Use.
Condom use
Nevera
25%b
50%c
75%d
100%e
IDWTAf

M
5.90
6.00
4.77
7.52
6.18
4.85

SD
3.68
3.32
2.62
3.68
3.51
3.81

F
2.29

df
(5, 294)

p
.046

ƞ2
.038

Susceptibility

Nevera
25%b
50%c
75%d
100%e
IDWTAf

9.45
8.82
11.61
10.21
9.48
9.28

3.94
3.34
3.36
3.65
4.13
4.51

0.94

(5, 294)

.454

.016

Seriousness

Nevera
25%b
50%c
75%d
100%e
IDWTAf

19.90
20.18
23.23
21.72
20.87
20.73

6.99
4.47
6.00
4.98
6.00
6.88

0.73

(5, 294)

.596

.012

Benefits

Nevera
25%b
50%c
75%d
100%e
IDWTAf

15.67
16.45
15.31
15.41
16.01
16.30

3.36
2.62
3.22
3.41
3.23
2.95

0.49

(5, 294)

.786

.008

Barriers

Nevera
25%b
50%c
75%d
100%e
IDWTAf

30.57
29.45
34.62
31.86
27.81
29.40

8.61
7.94
8.71
10.57
8.56
10.17

2.44

(5, 294)

.035

.040

Knowledge

Nevera
39.74
6.45
1.48
(5, 294)
.198
.024
25%b
36.73
10.55
50%c
39.08
6.06
75%d
39.59
6.66
e
100%
41.08
6.63
IDWTAf
38.98
7.98
Notes. na = 42, nb = 11, nc = 13, nd = 29, ne = 165, nf = 40, Total n = 300, IDWTA = I don’t want to answer
Self-efficacy
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Table 14. Differences in Subscale Scores by Number of Sexual Partners.
Number of M
SD
F
df
p
Sex
partners
Knowledge
Zeroa
5.39
3.59
3.10
(3, 296)
.027
b
One
6.23
3.58
Twoc
7.45
3.24
d
IDWTA
5.07
3.60

ƞ2
.030

Susceptibility Zeroa
Oneb
Twoc
IDWTAd

9.44
10.02
8.52
7.86

3.95
4.21
3.50
3.55

2.20

(3, 296)

.089

.022

Seriousness

Zeroa
Oneb
Twoc
IDWTAd

20.40
21.32
20.59
19.71

6.89
5.77
5.35
6.22

0.662

(3, 296)

.576

.007

Benefits

Zeroa
Oneb
Twoc
IDWTAd

15.64
16.22
15.59
15.29

3.70
3.01
2.73
2.27

1.01

(3, 296)

.390

.010

Barriers

Zeroa

30.26

2.00

(3, 296)

.114

.020

Oneb
Twoc
IDWTAd

28.37
27.93
33.21

10.0
0
8.46
9.01
8.87

Zeroa
38.76 7.50
2.69
(3, 296)
.047
.027
Oneb
40.77 6.83
Twoc
42.31 5.69
d
IDWTA
39.57 5.94
Note. na = 96, nb = 161, nc = 29, nd = 14, Total n = 300, IDWTA = I don’t want to answer.
Self-efficacy

Clinical variables. For the purpose of this study clinical variables consist of BMI,
CD4+ T lymphocyte count, HIV viral load, encouragement, depression, and history of
abnormal Pap smear (participants-reported and medical chart documented). This section
presents data about relationships between subscale variables and clinical variables. The
relationship between depression and the subscale variables was not
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Table 15. Differences in Subscale Scores by Sexual Experience.
Sexual
Mean
SD
F
df
Activity
Knowledge
Currently
6.56
3.63
5.04 (2, 296)
activea
Not activeb
5.63
3.47
Neverc
2.83
2.32
Susceptibility Currently
activea
Not activeb
Neverc

9.78

4.09

9.41
9.67

4.04
4.27

Seriousness

Currently
activea
Not activeb
Neverc

21.09

5.58

20.68
20.67

6.56
9.56

Currently
activea
Not activeb
Neverc

16.14

2.86

15.82
13.33

3.47
4.08

Currently
activea
Not activeb
Neverc

28.41

8.38

29.69
35.33

9.54
14.25

Benefits

Barriers

Self-efficacy

Currently
40.99 6.50
activea
Not activeb
39.93 6.75
c
Never
27.83 12.43
Note: na = 151, nb = 142, nc = 6, Total n = 300.

p

ƞ2

.007

.033

0.31

(2, 296)

.735

.002

0.17

(2, 296)

.092

.001

2.41

(2, 296)

.092

.016

2.14

(2, 296)

.119

.014

11.19

(2, 296)

<.01

.070

statistically significant (Table 16). The relationship between CD4+ T-lymphocyte and the
subscale variables was not statistically significant (Table 21).
HIV viral load. Women with low viremia (VL <500) perceived more benefits to
cervical cancer screening than women with high viremia (p=.032, ƞ2 = .015). However,
ANOVA is not robust against unequal group size when the assumption of homogeneity
has been violated. Welch’s adjust F ratio was utilized, and the difference between HIV
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Table 16. Differences in Subscale Scores by Medical Chart Documented History of
Depression.
Depression
Mean SD
F
df
p
ƞ2
a
Knowledge
Yes
6.08
3.41
0.05
(1, 298)
.821
.000
Nob
5.98
3.72
Susceptibility

Yesa
Nob

9.74
9.47

4.09
4.04

0.34

(1, 298)

.560

.000

Seriousness

Yesa
Nob

21.53
20.38

5.92
6.25

2.63

(1, 298)

.106

.001

Benefits

Yesa
Nob

15.57
16.20

3.13
3.23

2.90

(1, 298)

.090

.015

Barriers

Yesa
Nob

29.85
28.64

9.29
8.94

1.30

(1, 298)

.256

.005

Self-efficacy

Yesa
Nob

39.38
40.85

6.38
7.35

3.31

(1, 298)

.070

.014

Note: na = 129, nb = 171, Total n = 300.
viral load and perceived benefits is not statistically significant, Welch’s F(1, 74.84) =
3.46, p = .067. Women with low viremia had higher perceived self-efficacy scores than
women with high viremia (p =.042, ƞ2 = .014). Differences between HIV viral load and
the following subscale variables: knowledge, susceptibility, seriousness, and barriers
were not statistically significant (p = .554, p = .211, p = .720, respectively) (Table 17).
Encouragement. Women who reported being encouraged by providers to get a
Pap smear had higher HPV knowledge scores than women who reported that they were
not encouraged. Perceived self-efficacy and benefit scores were higher for women who
reported being encouraged than for women who reported that they were not encouraged
by providers. The differences were statistically significant, but ANOVA is not robust
when the assumption of homogeneity is violated in the presents of unequal group size, so
Welch’s F ration was calculated. Welch’s adjusted F ratio was obtained for perceived
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benefits and self-efficacy, [Welch’s F(1, 41.89) = 10.47, p = .002; Welch’s F(1, 40.00) =
12.78, p = .001, respectively] (Table 18)
Table 17. Differences in Subscale Scores by HIV Viral Load.
Knowledge

HIV Viral load
Low viremiaa
High viremiab

Mean
6.04
5.97

SD
3.56
3.77

F
0.02

df
(1, 298)

p
.892

ƞ2
.000

Susceptibility

Low viremiaa
High viremiab

9.55
9.76

4.13
3.76

0.13

(1, 298)

.720

.000

Seriousness

Low viremiaa
High viremiab

20.98
20.45

6.08
6.33

0.35

(1, 298)

.554

.001

Benefits

Low viremiaa
High viremiab

16.12
15.12

3.01
3.82

4.63

(1, 298)

.032

.015

Barriers

Low viremiaa
High viremiab

28.83
30.50

9.00
9.47

1.57

(1, 298)

.211

.005

Low viremiaa
40.62
6.54
4.15
(1, 298)
.042
High viremiab
38.55
8.42
Note: na = 242, nb = 58, Total n = 300. Barriers: Welch’s F(1, 74.84) = 3.46, p = .067.
Self-efficacy

Table 18. Differences in Subscale Scores by Encouragement by Providers.
Knowledge

Susceptibility

Seriousness

Benefits

Barriers

.014

Encouragement
Yesa
Nob

M
6.43
4.03

SD
3.46
3.51

F

df

p

ƞ2

15.56

(1, 219)

<.01

.051

Yesa
Nob

9.67
9.60

4.00
4.52

0.01

(1, 291)

.914

.000

Yesa
Nob

21.14
19.90

6.00
6.48

1.37

(1, 291)

.242

.005

Yesa
Nob

16.17
13.95

2.97
4.02

16.37

(1, 291)

<.01

.053

Yesa
Nob

28.95
31.00

8.93
10.50

1.62

(1, 291)

.204

.006

Yesa
40.95 6.12
26.02
(1, 291)
<.01
.082
Nob
34.92 10.00
Note. an= 256, bn = 37, Total n = 293. Benefits: Welch’s F(1, 41.89) = 10.47, p = .002. Selfefficacy: Welch’s F(1, 40.00) = 12.78, p = .001.
Self-efficacy
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Participant-reported history of abnormal Pap. Women who reported having a
history of an abnormal Pap smear perceived themselves to be more susceptible to cervical
cancer, and they perceived cervical cancer to be more serious than women without a
history of having an abnormal Pap smear. Women who reported having a history of an
abnormal Pap smear perceived more benefits and fewer barriers to Pap smears than
women without a history of having an abnormal Pap smear. Women who reported
having a history of an abnormal Pap smear had higher perceived self-efficacy and
knowledge scores than women who denied having a history of an abnormal Pap smear
(Table 19).
Table 19. Differences in Subscales Scores by Participant Reported History of Abnormal
Pap Smear.
Abnormal Pap
Yesa
Nob

M
6.68
5.40

SD
3.63
3.43

F
9.88

df
(1, 297)

p
.002

ƞ2
.032

Susceptibility

Yesa
Nob

10.58
8.60

4.15
3.74

18.85

(1, 297)

<.01

.060

Seriousness

Yesa
Nob

21.60
20.17

5.70
6.48

4.12

(1, 297)

.043

.014

Benefits

Yesa
Nob

16.39
15.44

2.80
3.50

6.72

(1, 297)

.010

.022

Barriers

Yesa
Nob

27.62
30.64

8.16
9.74

8.47

(1, 297)

.004

.028

Yesa
41.75
Nob
38.69
Note. an= 150, bn = 149, Total n = 299.

6.19
7.42

15.03

(1, 297)

<.01

.048

Knowledge

Self-efficacy

Medical chart documented history of abnormal Pap. Medical records were
reviewed for history of an abnormal Pap smear. Participants whose charts indicated a
history of an abnormal Pap smear had higher perceived susceptibility than women whose
charts did not reflect a history of an abnormal Pap smear, differences were statistically
significant (p = .008) (Table 20).
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Table 20. Differences in Subscale Scores by Medical Chart Document History of
Abnormal Pap smear.
Abnormal Pap
Yesa
Nob

M
6.31
5.76

SD
3.88
3.42

F
1.62

df
(1, 282)

p
.204

ƞ2
.006

Susceptibility

Yesa
Nob

10.31
9.00

4.26
3.92

7.15

(1, 282)

.008

.025

Seriousness

Yesa
Nob

21.43
20.54

5.93
6.38

1.41

(1, 282)

.236

.005

Benefits

Yesa
Nob

16.30
15.72

2.81
3.50

2.15

(1, 282)

.144

.008

Barriers

Yesa
Nob

28.62
29.40

8.52
9.59

0.50

(1,282)

.479

.002

Yesa
40.91
7.37
1.91
Nob
39.72
6.94
Note: na = 115, nb = 169, missing = 16, Total n = 284.

(1, 282)

.167

.007

Knowledge

Self-efficacy

BMI. Bivariate correlations were used to determine relationships between BMI
and the subscale variables. A statistically significant but weak correlation between BMI
and perceived benefits exists (r = .127, p = .027); therefore, women with a higher BMI
perceived more benefits. A weak but statistically significant correlation between BMI and
perceived barriers exists (r = -.118, p = .041), so women who perceive more barriers had
a lower BMI (Table 21).
Aim Three
Logistic regression was used to assess the ability of the subscale variables
(CHBM, CSE, and HPV knowledge) and select demographic factors to predict Pap
testing among women infected with HIV. The outcome variables were participantreported Pap smear and medical chart documented Pap smear. Predictors were selected
from existing literature.
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Table 21. Pearson’s Correlations for Age, CD4 Count, and Subscale Variables.
Variables
1
2
3
4
5
6
7
8
9
Age (1)
CD4 Count (2)

1
.155**

1

Susceptibility (3) -.140* -.009

1

Seriousness (4)

-.036

.006 .368**

Benefits (5)

-.002

.035

Self-efficacy (6) -.155** .057
Barriers (7)
Knowledge (8)
BMI (9)

.038

1

-.054 .130*
-.039

1

.005 .534**

1

-.094 .284** .290** -.191** -.455**

-.292** -.036 .094

1

.076 .157** .297** -.176**

-.042 .265** -.064 -.013 .127*

.098

1

-.118* .040 1

Note. n = 300. p = < 0.01**, p < 0.05*.
For participant-reported last Pap smear, all variables were entered into the initial
equation and perceived barriers was significant, p = .006, OR = .944. A backward
stepwise approach was taken in eliminating potential predictor variables that were not
significant. The following predictors were retained in the analysis: perceived
susceptibility, perceived barriers, age, CD4+ T lymphocyte count, family history and
HPV knowledge The results revealed that last CD4+ T lymphocyte count and perceived
barriers and susceptibility were statistically significant predictors of participant-reported
last Pap smear (p = .046, p <.001, and p = .004, respectively). Perceived barriers and last
CD4+ Tlymphocyte count are statistically significant predictors when they are the only
two variables in the equations, p = .000, OR = 0.946, 95% CI [0.918 – 0.975]; p = .002,
OR = 1.002, 95% CI [1.001 – 1.002] (Table 22).
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Table 22. Multiple Logistic Regression of Participant Reported Pap Smear.
Model
β Error Sig.
O.R
95% C.I.for O.R.
Lower
Upper
Susceptibility
.081 .039 .041 1.084
1.003
1.171
Barriers
Age
CD4 Count
Family history
Knowledge

-.072

.017 <.001

.930

.899

.963

.005

.014

.713

1.005

.979

1.032

.001

.000

.004

1.001

1.000

1.002

.326

.372

.381

1.386

.668

2.876

-.052

.052

.320

.950

.858

1.052

Constant
1.692 1.032 .101 5.431
Note. n = 300, Family history = participant knowing that family history of cervical cancer
is a risk factor. Model (likelihood ratio) χ2 = 32.15, p <.01. Nagelkerke R2 = .15.
For medical chart documented last Pap smear, all variables were entered into the
initial equation and no predictors were revealed. Using the same predictors used to
predict participant reported Pap smear, the following predictors: perceived susceptibility,
perceived barriers, age, CD4+ T lymphocyte, family history and HPV knowledge were
used in the analysis. CD4+ T lymphocyte was a statistically significant predictor of
medical chart-reported last Pap smears (p = .038), but the full model was not statistically
different from the null model, a model without predictors (p = .392). Therefore there are
no predictors for medical chart documented Pap smear (Table 23).
Cronbach’s Alpha
Cronbach’s alpha was calculated for the following subscales: perceived
susceptibility, benefits, barriers, seriousness and self-efficacy. Perceived susceptibility
and self-efficacy scales had excellent internal consistency (α > .90). The internal
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consistency for perceived seriousness, perceived barriers and the knowledge scales was
good. The perceived benefits scale had a Cronbach’s alpha that is interpreted as
acceptable (Table 24).
Table 23. Multiple Logistic Regression of Medical Chart Documented Pap Smear.
Model
β
Error Sig. O.R 95% C.I. for O.R.
Lower
Upper
Susceptibility
.017
.031 .575 1.018
.958
1.081
Barriers
Age

-.015

.014 .293

.985

.959

1.013

-.001

.012 .934

.999

.977

1.022

.001

.000 .038

1.001

1.000

1.002

-.029

.303 .923

.971

.536

1.758

.004

.043 .928

1.004

.923

1.092

CD4 Count
Family history
Knowledge

Constant
-.439
.875 .616
.645
Note. n = 300, Family history = participant knowing that family history of cervical cancer
is a risk factor. Model (likelihood ratio) χ2 = 6.29, p = .392. Nagelkerke R2 = .28.
Table 24. Reliability of Subscales.
Subscales
Number of items
Perceived
4
Susceptibility

Cronbach’s Alpha
.92

Interpretation
Excellent

Perceived
Seriousness

7

.85

Good

Perceived Benefits

4

.72

Acceptable

Perceived Barriers

14

.89

Good

Perceived Selfefficacy

10

.92

Excellent

15

KR-20
.81

Good

HPV Knowledge
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Pap Smear by Source
The outcome variable for the current study was Pap smear adherence, but there
were two possible sources for last Pap smear, participant-reported and medical chart
documented. The number of women who had not received a Pap smear during the past
year nearly doubled when the source changed from participant to medical chart (Table 4).
McNemar test (S) was performed to assess the relationship between medical chart
documented last Pap smear and participant-reported last Pap smear because the two
variables are correlated. The relationship was statistically significant, S (1, N= 300) =
74.9, p <.001. Women who reported having a Pap smear during the past year were more
likely to have a Pap smear documented in their medical chart. Women who reported
having a Pap smear greater than 1 year ago were more likely to have a Pap smear
documented in their chart greater than 1 past year ago (Table 25).
Table 25. Crosstabs Table of Pap Smear by Source
Pap Smear
Participant reported
Medical Chart
Yes
No
Yes
121
10
No

103

S

ϕ

74.9**

.36**
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Note. n = 300. ** = p < .001.
Abnormal Pap Smear by Source
Information regarding history of having an abnormal Pap smear was obtained
from the participant and the medical chart. McNemar test (S) was performed to assess the
relationship between medical chart documented and participant-reported history of
having an abnormal Pap smear because the two variables are correlated. The majority of
women who reported not having a history of an abnormal Pap smear were the same
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women who did not have a documented history of an abnormal Pap smear.
Approximately 28% of the women’s response did not match their medical chart (Table
26).
Table 26. Crosstabs Table of History of an Abnormal Pap Smear by Source
History of Abnormal Pap Smear
S
Participant reported
Medical Chart
Yes
No
Yes
87
28
7.62*
No

54

114

Note. n = 283. * = p < .01. ** = p < .001.
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ϕ

.43**

Chapter Five: Discussion

HIV-infected women are at increased risk for developing cervical dysplasia and
cancer as a result of HPV-infection (ACOG, 2010; Tello et al., 2010; Aberg et al., 2009);
However, HIV-infected women are not receiving Pap testing according to ACOG
guidelines (Leece et al., 2010). Approximately 25% of HIV-infected women had not
received their annual Pap smear during the previous year (Rahangdale, Sarnquist, Yavari,
Blumenthal & Israelski, 2010; Tello et al., 2010; Oster, Sullivan & Blair, 2009; Stein et
al., 2001; Solomon et al., 1998). Many reasons have been cited to explain poor test
adherence such as age, race/ethnicity, tobacco use, weight, education, ability to pay, risky
behaviors, HIV viral load, CD4-lymphocyte count, and perceived susceptibility,
seriousness, benefits, and barriers. Currently, the literature is lacking a comprehensive
study evaluating relationships between Pap test adherence and numerous cited variables;
thus, useful information for clinicians is needed to help them identify women at risk for
poor adherence to cervical cancer screening.
The purpose of the study was to evaluate HIV-infected women’s knowledge of
cervical cancer and HPV, perceived susceptibility to cervical cancer, and their attitudes
regarding the severity of cervical cancer. Further, the study assessed the women’s
perceived self-efficacy, benefits, and barriers to cervical cancer screening. In addition,
predictors of cervical cancer screening in HIV-infected women were evaluated. This
64

chapter discusses the findings of the study in light of existing literature, states limitations
and strengths of the study, offers recommendations for future research, and discusses
implications for practice. The study determined the following: a) the relationships
between the Health Belief Model subscale variables and Pap smear adherence, b) the
relationships between the subscale variables and selected demographic factors, and c) the
ability of the subscale variables and demographic factors to predict Pap smear adherence.
Results differed based the source of data about on Pap smear (participant-reported versus
medical chart documented).
Sample Characteristics
The current study had the lowest mean knowledge score (6.02) compared to data
reported in existing studies (Denny-Smith, Bairan & Page, 2006; Ingledue et al., 2004;
Montgomery, Bloch, Bhattacharya & Montgomery, 2010). About half (50.3%) of the
women in the current study reported having a high school diploma, and 33% reported
having less than a high school education. Three previous studies used the HPV/cervical
cancer knowledge questionnaire in samples of college women, nursing students and
women ages 40 – 70 (Denny-Smith, Bairan & Page, 2006; Ingledue et al., 2004;
Montgomery, Bloch, Bhattacharya & Montgomery, 2010). The highest mean knowledge
score was in female nursing students (n = 240, M = 10.2, range of 1 -15) (Denny-Smith,
Bairan & Page, 2006). The majority, 71 – 100 %, of participants in the other studies had
some college which may account for the difference in knowledge scores. Further studies
are needed to determine the effect of level of education on health literacy. .
Women in the study did not feel susceptible to cervical cancer (M = 9.59, range 420), nor did they think that cervical cancer was serious (M = 20.88, range 7 – 35).
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Numerous studies have used Champion’s HBM scales to evaluate perceived
susceptibility and severity to cervical cancer, but for unknown reasons, items were added
or deleted. Despite the various score ranges, women in earlier studies did not feel they
were susceptible to cervical cancer (Allahverdipour & Emami, 2008; Boonpongmanee &
Jittanoon, 2007; Burak & Meyer, 1997; Denny-Smith et al., 2006: Ingledue et al., 2004;
Montgomery, Bloch, Bhattacharya & Montgomery, 2010; Ho et al., 2005; Park, Chang &
Chung, 2005). Similar results were documented for perceived severity, except for the
results of two studies which stated that women agreed or understood that cervical cancer
was serious, but the questions that measured seriousness were not about the participants’
personal perception (Byrd et al., 2004; Guilfoyle et al., 2007). For example, one question
stated, “cervical cancer is not as serious as other types of cancers” (Byrd et al.,
2004).Further studies are needed to determine the reason for low susceptibility score in
women infected with HIV. It is possible that HIV-infected feel that they are destined for
death related to their HIV or are overwhelmed with their HIV diagnosis that are chronic
diseases seem miniscule. Futures studies may consider determining the effects of
fatalistic attitudes on Pap smear adherence and perceived susceptibility.
In the current study, women perceived that Pap smears were beneficial, (M =
15.93; range 4 - 20), and the majority of women did not believe they had barriers
preventing them from getting a Pap smear (M = 29.16, range 14 – 56) (Table 4). The
literature supports this finding (Byrd et al., 2004; Ho et al., 2005; Park, Chang & Chung,
2005). Note that perceived benefits and barriers were not measured using the same
subscale, but variations of Champion’s HBM.
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Women in the study believed that they could request a Pap smear from their
health provider(s) (M = 40.22, range 10-50). To date, no studies have used Champion’s
Self-efficacy scale to evaluate cervical cancer screening; therefore, the current literature
cannot be linked to results of this study. Women receiving care from the Specialty Care
Clinic may feel comfortable in requesting Pap smears and discussing intimate
information because providers ask questions at each visit about risky behaviors including
recent sexual encounters. It is essential for researchers to further study the relationship
between perceived self-efficacy and Pap smear adherence.
Aim One
The purpose of this section was to evaluate the relationship between Pap test
adherence in women infected with HIV and the following variables: CHBM, CSE,
HPV/cervical cancer knowledge scale. There are two outcome variables: participant
reported last Pap smear during the past year (yes or no) and medical chart documented
last Pap smear during the past year (yes or no).
One would expect that women who received their Pap smear during the past year
would have higher knowledge scores; and perceived susceptibility, seriousness, benefits,
and self-efficacy scores; and lower perceived barriers scores. Most of the findings from
the current study did not support that conclusion, but statistically significant differences
were revealed for perceived barriers and self-efficacy.
Pap smear.
Knowledge. Differences in knowledge scores by last reported or documented Pap
smear were not statistically significant. In the current study, women had knowledge
deficits regarding HPV and cervical cancer. Future studies may want to consider creating
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an intervention to increase HPV and cervical cancer knowledge using pre- and posttesting to evaluate the impact of the intervention on Pap smear adherence. In the current
study knowledge was not directly related to Pap smear adherence, but knowledge was
related to perceived barrier and self-efficacy, which were both related to Pap smear
adherence.
Perceived seriousness and susceptibility. Women in the current study did not
differ in their perceptions regarding the seriousness of cervical cancer and their personal
susceptibility to cervical cancer based on their last reported or medical chart documented
Pap smear. The findings are in agreement with previous studies (Allahverdipour &
Emami, 2008; Boonpongmanee & Jittanoon, 2007; Burak & Meyer, 1997; Denny-Smith
et al., 2006: Ingledue et al., 2004; Montgomery, Bloch, Bhattacharya & Montgomery,
2010; Ho et al., 2005; Park, Chang & Chung, 2005). It is possible that perceived
seriousness to cervical cancer and HPV does not explain Pap smear adherence, but
perceived susceptibility is a predictor of Pap smear adherence. Therefore, further research
is needed.
Perceived benefits. Perceived benefit scores did not differ by last participantreported or medical chart documented Pap smear (Tables 4 & 5). The findings of the
current study do not agree with existing research. The current study is the first to evaluate
HIV-infected which may account for the variations in the findings between the current
study and existing studies. Further research regarding factors that influence cervical
cancer screening should not focus on benefits of cervical cancer screening.
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Aim Two
The purpose of this section was to evaluate the relationships between subscale
variables (CHBM scale, CSE scale, HPV/cervical cancer knowledge) and selected
demographic factors in HIV-infected women. To date, there is no published data
evaluating differences in subscale variables by sociodemographic, risky behavior and
clinical variables with regard to cervical cancer.
Sociodemographic.
Race. Caucasian women in the current study perceived themselves to be more
susceptible to cervical cancer than Black women. The reason for the finding is unknown,
but in this study susceptibility was correlated with barriers and seriousness. Further study
is needed in African American women to determine their understanding of susceptibility
and their personal risk for cervical cancer.
Education. In the current study, there are differences in knowledge, perceived
benefits, barriers and self-efficacy by education (Table 10). As the level of education
increased, knowledge increased, benefits scores increased, fewer barriers were perceived
and self-efficacy scores increased. The finding is reasonable because knowledge is
significantly correlated with self-efficacy, benefits and barrier. According to the current
study, as knowledge increased benefits and self-efficacy increased and barriers decreased
(p < .001). Future interventions should focus on increasing knowledge and perceived selfefficacy of women with a high school education or less.
Age. As women aged, their knowledge regarding HPV and cervical cancer
decreased (Table 21); this is an expected finding. In the current study the average age was
approximately 45 and the mean knowledge scores were low. It should be noted that the
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first HPV prevention vaccine was approved in 2006 for females ages 9 - 26; therefore,
older women are not the target of HPV prevention campaigns and may not be as
knowledgeable as younger women (CDC, 2011). The same rationale can be used for
older women feeling less susceptible to HPV and cervical cancer. Women over the age of
26 may not feel susceptible because the vaccine is not recommended for them. Further
research is needed.
Risky behavior.
Cigarette use. Women who reported cigarette use felt more susceptible to cervical
cancer. Although not statistically significant, they were more knowledgeable about
cervical cancer and HPV, which is a reasonable finding. Providers are successfully
conveying to patients that cigarette use increases their risk of cancer.
Condom use. There is an association between condom and the following subscale
variables: perceived barriers and HPV knowledge. Perceived barriers and knowledge
have a negative weak relationship, therefore, it would be expected that women who
reported using condoms 75% of time would have lower perceived barrier scores than
women who reported using condoms 100% of the time because the former had higher
knowledge scores. Several women (165) reported always using condom which could be
the results of social desirability responses, which increases the possibility of error.
Clinical variables.
HIV viral load. Women with low viremia were more confident in their ability to
request a Pap smear than women with high viremia. Women with low viremia are taking
antiretroviral medication to suppress HIV, which means that they are more likely to be
adherent to scheduled appointments and have an establish rapport with their provider(s);
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therefore increasing their confidence to request services. The relationship between selfefficacy regarding Pap smear adherence and HIV viral load was explored for the first
time in the current study. However, existing studies have documented that women with
lower viremia are more likely to adhere to Pap smears (Baranoski et al., 2011; Tello et
al., 2010). Further study is needed to explain the relationship between HIV viral load and
Pap smear adherence.
Subscale variables. Perceived susceptibility and seriousness were positively
correlated, but the relationship was weak; so as susceptibility increases severity increases.
This finding is supported by three studies conducted in women from various backgrounds
and ages (Allahverdipour & Emami, 2008; Denny-Smith, Bairan & Page, 2006;
Montgomery, Bloch, Bhattacharya & Montgomery, 2010). Despite the significant
correlations between perceived susceptibility and seriousness, their relationship to Pap
smear adherence was not significant, but perceived susceptibility was a significant
predictor of Pap smear adherence. Therefore, researchers should not focus on perceived
seriousness in future studies regarding Pap smear adherence.
There was a negative weak significant relationship between perceived barriers and
benefits (Table 21). Women who perceived more benefits to cervical cancer screening
perceived fewer barriers to cervical cancer screening. Existing studies support the finding
(Allahverdipour & Emami, 2008; Lee, Fogg & Menon, 2008). Further studies should
examine barriers that prevent women for adhering to Pap smears per ACOG guidelines
via quantitative or qualitative research.
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Aim Three
Aim 3 assessed the ability of the subscale (CHBM and CSE, and knowledge) and
select demographic variables to predict Pap testing in women infected with HIV.
Perceived susceptibility, barriers and last CD4+ T lymphocyte count predicted last Pap
smear (Table 22). The variables did not predict medical chart documented Pap smear
(Table 23).
In the current study, variables entered to the equation did not predict medical
chart documented Pap smear (Table 23). Frequently providers request records from other
facilities and upon receipt the records are lost, misplaced, or not enter into the electronic
medical record system, which would result in women being incorrectly labeled as not
having a Pap smear during the past year. A retrospective chart review study conducted at
Johns Hopkins HIV clinic revealed that age, CD4+ T lymphocyte count and illicit
substance use were predictors of Pap smear adherence (Tello et al., 2010). The study
included approximately 1,100 participants receiving care from a clinic that provided
gynecological and primary services in the same building which may improve
documentation of last Pap smear. More HIV providers and clinics may want to consider
offering multiple services in one building to increase adherence.
The current study revealed that perceived barriers and last CD4+ T lymphoctyte
count are significant predictors of participant-reported last Pap smear when they are the
only two variables retained in the equation. Existing research supports the currents
study’s finding that perceived barriers is a significant predictor of Pap testing
(Boonpongmanee & Jittanoon, 2007; Allahverdipour & Emami, 2008; Lee, Fogg, &
Menon, 2008; Ho et al., 2005). In addition, perceived susceptibility was a significant
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predictor of participant-reported last Pap smear only in the presence of perceived
barriers, age and knowing that a family history of cervical cancer is a risk factor for
cervical cancer. There was a significant, weak relationship between perceived
susceptibility and age, and perceived susceptibility and barriers which is a potential
reason for perceived susceptibility being a significant predictor of participant-reported
last Pap smear which is a potential reason for the findings.
Cronbach’s Alpha
Cronbach’s alpha was calculated for measures used in the study to evaluate the
reliability of each subscale (Table 24). Overall the subscales had good internal
consistency except perceived benefits. The perceived benefits subscale had acceptable
internal consistency (α = .72). A Cronbach’s alpha of .72 is acceptable, but the goal for a
seasoned scale is .80 or higher (Gliem & Gliem, 2003). Removing item 31 would
increase Cronbach’s alpha from .72 to .75. The perceived benefits scale for the current
study was revised to reflect cervical cancer, rather than breast cancer. Victoria Champion
created the scale in 1984 for breast self-examination (Champion, 1984). Gulten, Akyuz
and Acikel (2010) adapted CHBM scales for cervical cancer and Pap smear testing, but
instead of the perceived benefits scale consisting of four items the adapted scale consisted
of seven. Four of the seven items measured benefits perceived and health motivations. It
should be noted that health motivation is a separate concept developed by Victoria
Champion (1984). For the current study only the four items that measure perceived
benefits were retained. Cronbach’s alpha is influenced by the number of items in the
scale. It is possible that shortening the scale weakened it; therefore, utilization of the
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subscale perceived benefits subscale for cervical cancer in the current study is novel and
further research is needed to determine the reliability of the subscale.
Strengths
The current study is novel in that it evaluates Pap test adherence in HIV-infected
women using the HBM more specifically the adapted CHBM and CSE scales. The
current study utilized more variables from the HBM to assess Pap smear adherence than
the existing body of literature. CHBM and CSE scales were adapted for use in cervical
cancer by a researcher in Turkey, so the current study is the first in the U.S.A to utilize
the adapted scale. The current study contributes to the current body of literature.
Limitations
The study has several limitations in its design and sampling; therefore, the
generalizability of the findings may be limited. The study used a sample of convenience
selected from two local ambulatory specialty care clinics, which may introduce selection
bias. The participants were currently in care which excluded women who are potentially
at greater risk due to lack of care. Future studies should include women not receiving
regular care. The survey consisted of 76 items delivered via paper, which could lead
participants to become fatigued and randomly select answers, which could increase error
variance. Women may have selected answers that were socially desirable, which could
result in bias. There are other clinics that serve HIV-infected women, but only women at
the two research sites were eligible to participate.
Implications for Nursing
Practice. Health care providers should provide women with accurate and detailed
information regarding HPV, cervical cancer, and Pap smears. This is particularly
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important for women infected with HIV. Women should continue to be encouraged to
obtain Pap smears per current guidelines. Barriers to Pap smear adherence should be
addressed and eliminated or minimized when possible. Providers may want to consider
completing Pap smears during a scheduled follow-up visit and not scheduling a separate
gynecology appointment. Women had some knowledge deficits about HPV and cervical
cancer; therefore educational material regarding HPV, cervical cancer and Pap smears
should be available in various formats such as printed and audiovisual. Providers should
complete educational activities to increase their awareness and knowledge. Having a
better understanding can lead providers to be better advocates for Pap smears.
Technology is a big part of healthcare so providers can search for a system that alerts
them when patients’ Pap smears are due.
Research. Participants in the current study had knowledge deficits regarding
HPV and cervical cancer and a poor understanding of the Pap smear procedure.
Knowledge deficits in patients could be a reflection of knowledge deficits in providers.
Future studies should focus on assessing healthcare providers’ knowledge of cervical
cancer, HPV, and current ACOG guidelines. Existing research has linked inadequate
health literacy to knowledge deficit (Gazmararian, Williams, Peel & Baker, 2003;
William, Baker, Parker & Nurss, 1998). Understanding health information, including labs
such as CD4+ T lymphocytes count and HIV viral load, may lead patients to make better
health-related decisions. Therefore, Researchers should evaluate the effects of health
literacy and numeracy on HPV/ cervical cancer knowledge in HIV-infected women.
In the current study, women with more confidence in their ability to request a Pap
smear were more likely to have had a Pap smear within the past year, and perceived
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susceptibility, barriers and last CD4+ T lymphocyte count were predictors of Pap smear
adherence, and women lacked knowledge of HPV and cervical cancer. Due to high
internal consistency of the perceived self-efficacy scale, the current instruments should be
used in socially diverse population. Future interventions should focus in decreasing
barriers, increasing adherence to antiretroviral medications to increase CD4+ T
lymphocyte counts and increasing women’s perceived risk of developing cervical cancer.
Since women lacked knowledge, future studies could focus on how HIV-infected women
receive health-related information. Qualitative research is vital in understanding factors
that influence cervical cancer screening in HIV-infected women.
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Appendix A: Florida DOH IRB Approval Letter
May 14, 2012

To: Crystal Chapman-Lambert
Protocol Title: Predicting Factors that Influence Cervical Cancer Screening in HIVinfected Women: Using the Health Belief Model.
DOH IRB Number: H12014
Protocol Approval Date: May 14, 2012
Protocol Expiration Date: May 13, 2013
The Department of Health Institutional Review Board, or representative, determined your
study involves no more than minimal risk and meets the criteria for expedited review. It
has been granted expedited approval. The study is approved for implementation.
As a reminder, the IRB must review and approve all human subjects research protocols at
intervals appropriate to the degree of risk, but not less than once per year. You are
responsible for completing a continuing review application for this project at least
60 days prior to the expiration date of : May 13, 2013. Action is required even if
your study is closing. Failure to complete an application for continuing review at least
60 days in advance of expiration is considered non-compliance by the Department of
Health, and may result in closure of the study, reporting to institutional officials, and
reporting to federal regulatory authorities, and suspension of funding, if funded by DOH.
Under federal regulations, if the IRB does not approve an application to continue
research prior to expiration, then authorization to continue research expires automatically
and all research must stop. Federal regulations do not allow any "grace" period or allow
research to continue once authorization expires (except in limited circumstances).
Investigators are required to notify the IRB in writing as soon as possible, but within 5
working days, of the occurrence of any adverse events, unanticipated problems, injuries,
side effects, deaths, other problems involving risks to subjects, or deviations from federal
or state regulations, or DOH policy.
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The IRB has approved exactly what was submitted. Any revisions to this protocol or
consent form, no matter how minor, must be presented to the IRB for review and
approval before implementation of the changes, except where necessary to eliminate
hazard to human subjects. If a change is required to eliminate an immediate hazard, the
IRB should be notified as soon as possible but no later than 5 working days.
Research records must be maintained for three years after completion of the research; if
the study involves medical treatment, it is recommended that records be maintained for
eight years.
If you have questions, want to offer suggestions, or talk with someone about this or other
projects, please contact the Department of Health IRB at (850) 245-4585 or toll-free in
Florida
(866)
433-2775.
You
may
also
visit
our
website
at: http://flpublichealthethics.net/
Thank you for your cooperation with the IRB.
Sincerely,

Meghan Kennedy
Administrator, Institutional Review Board

Federal Wide Assurance#: 00004682
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Appendix B: Informed Consent Document

Informed Consent to Participate in Research
Information to Consider Before Taking Part in this Research Study
IRB Study # ______________
You are being asked to take part in a research study. Research studies include only people
who choose to take part. This document is called an informed consent form. Please read
this information carefully and take your time making your decision. Ask the researcher to
discuss this consent form with you, please ask her to explain any words or information
you do not clearly understand.
Please tell the research study investigator if you are taking part in another research study.
We are asking you to take part in a research study called: Predicting Factors that
Influence Cervical Cancer Screening in HIV-Infected Women: Using the Health Belief
Model
The person who is in charge of this research study is Crystal Chapman Lambert.
The research will be conducted at Bartow Specialty Care Clinic and Hillsborough County
Specialty Care Clinic via a survey.
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Purpose of the study
•

The purpose of this study is to learn more about HIV-infected women’s
knowledge and perception of cervical cancer and cervical cancer screening.

•

As a women infected with HIV, you can provide information that can be used in
the future development of programs to increase cervical cancer awareness and
cervical cancer screening.

•

A PhD student attending USF College of Nursing is conducting the study for the
purpose of a dissertation.

Study Procedures
If you take part in this study, you will be asked to provide:
•

Information about your medical history and sexual history, and complete a pencil
and paper survey regarding your perceptions and knowledge about cervical cancer
and cervical cancer screening.
This study can be completed during one sitting and is expected to take less than 60
minutes.
The study will be conducted at Bartow Specialty Care Clinic and Hillsborough County
Specialty Care Clinic and the survey can be completed in a private area.
Total Number of Participants
It is expected that 300 women will volunteer in this study at Bartow Specialty Care Clinic
and Hillsborough County Specialty Care Clinic.
Alternatives
You do not have to participate in this research study.
Benefits
We are unsure if you will receive any benefits by taking part in this research study.
Risks or Discomfort
This research is considered minimal risk. That means that the risks associated with this
study are the same as what you face every day. There are no known additional risks to
those who take part in this study.
Compensation
You will be given a $15 Walmart gift card after completing the survey.
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Cost
There will be no additional costs to you as a result of being in this study. However,
routine medical care for your condition (care you would have received whether or not
you were in this study) will be charged to you or your insurance company.
Privacy and Confidentiality
We will keep your study records private and confidential. Certain people may need to
see your study records. By law, anyone who looks at your records must keep them
completely confidential. The only people who will be allowed to see these records are:
The research team, including the Principal Investigator, study coordinator, research
nurses, and all other research staff.
Certain government and university people who need to know more about the study.
For example, individuals who provide oversight on this study may need to look at
your records. This is done to make sure that we are doing the study in the right
way. They also need to make sure that we are protecting your rights and your
safety.
Any agency of the federal, state, or local government that regulates this research.
This includes the Food and Drug Administration (FDA), Florida Department of
Health (FDOH), FDOH Institutional Review Board and the Department of Health
and Human Services (DHHS) and the Office for Human Research Protection
(OHRP).
The USF Institutional Review Board (IRB) and its related staff, who have oversight
responsibilities for this study, staff in the USF Office of Research and Innovation,
USF Division of Research Integrity and Compliance, and other USF offices who
oversee this research.
We may publish what we learn from this study. If we do, we will not include your name.
We will not publish anything that would let people know who you are.
Voluntary Participation / Withdrawal
You should only take part in this study if you want to volunteer. You should not feel that
there is any pressure to take part in the study. You are free to participate in this research
or withdraw at any time. There will be no penalty or loss of benefits you are entitled to
receive if you stop taking part in this study
New information about the study
During the course of this study, we may find more information that could be important to
you. This includes information that, once learned, might cause you to change your mind
about being in the study. We will notify you as soon as possible if such information
becomes available.
87

Appendix B (Continued)
You can get the answers to your questions, concerns, or complaints
If you have any questions, concerns or complaints about this study, or experience an
adverse event or unanticipated problem, call Mrs. Crystal Chapman Lambert by email at
cchapman@health.usf.edu.
Call Florida Department of Health Institutional Review Board (DOH IRB) at (866) 4332775 (toll free in Florida) or 850-245-4585 If: 1) you have questions about your rights as
a participant in this study, general questions, or have complaints, concerns or issues you
want to discuss with someone outside the research or 2) If you have questions about your
rights as a person taking part in this research study.
Statement of Person Obtaining Informed Consent
I have carefully explained to the person taking part in the study what he or she can expect
from their participation. I hereby certify that when this person signs this form, to the best
of my knowledge, he/ she understands:
•

What the study is about;

•

What procedures/interventions/investigational drugs or devices will be used;

•

What the potential benefits might be; and

•

What the known risks might be.

I can confirm that this research subject speaks the language that was used to explain this
research and is receiving an informed consent form in the appropriate language.
Additionally, this subject reads well enough to understand this document or, if not, this
person is able to hear and understand when the form is read to him or her. This subject
does not have a medical/psychological problem that would compromise comprehension
and therefore makes it hard to understand what is being explained and can, therefore, give
legally effective informed consent. This subject is not under any type of anesthesia or
analgesic that may cloud their judgment or make it hard to understand what is being
explained and, therefore, can be considered competent to give informed consent.

______________________________________________________________________
Signature of Person Obtaining Informed Consent / Research Authorization
Date
_______________________________________________________________
Printed Name of Person Obtaining Informed Consent / Research Authorization
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1. Age (Please write a number. Do NOT write your date of birth) ___
2. Race/Ethnicity
a. Black/African American
b. White
3. Ethnicity
a. African American (non-Hispanic)
b. Caribbean (non-Hispanic)
c. Hispanic/Latina
d. Other
Please indicate ethnicity of you would like. ______________________
4. Marital Status
a. Single
b. Significant other
c. Married
d. Divorced
e. Widowed
5. Primary Language
a. English
b. Creole
c. Spanish
d. Other
6. Educational Level:
a. Less than a high school diploma
b. High school/trade school
c. College
7. Cigarette use
a. Yes
b. No
8. If yes:
a. Currently
b. Formerly
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9. Substance use (Cocaine, crystal-meth, or heroin)
a. Yes
b. No
10. If yes:
c. Currently
d. Formerly
11. How often do you use condoms?
a. Never
b. 25%
c. 50%
d. 75%
e. 100%
f. I don’t want to answer
12. Number of sexual partner during past year?
a. 0
b. 1
c. 2 or more
d. I don’t want to answer
13. Sexual experience:
a. Currently sexually active (during the past 12 months)
b. Not currently active
c. Never had sexual intercourse
14. Have you ever had a Pap test?
a. Yes
b. No
15. If yes, when was your last Pap test?
a. Within the past year
b. Within the past 2 years
c. Greater than 2 years
16. Have you ever been told that your Pap results were abnormal?
a. Yes
b. No
17. Do you feel like your doctor or nurse practitioner treats you differently because of
your race or ethnicity?
a. Yes
b. No
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18. Do you feel like your doctor or nurse practitioner treats you differently because of
your HIV/AIDS status?
a. Yes
b. No
For question 19- 57, please circle: Strongly disagree, Disagree, Neutral, Agree, or
Strongly agree.
Susceptibility
19. It is likely that I will get cervical cancer in the future.
Strongly disagree

Disagree

Neutral

Agree

Strongly agree.

20. There is a good possibility I will get cervical cancer in the next 10 years.
Strongly disagree

Disagree

Neutral

Agree

Strongly agree.

Agree

Strongly agree.

21. I feel I will get cervical cancer in the future.
Strongly disagree

Disagree

Neutral

22. I am more likely than the average woman to get cervical cancer.
Strongly disagree

Disagree

Neutral

Agree

Strongly agree.

Agree

Strongly agree.

Seriousness
23. The thought of cervical cancer scares me
Strongly disagree

Disagree

Neutral

24. When I think about cervical cancer, my heart beats faster
Strongly disagree

Disagree

Neutral

Agree

Strongly agree.

Agree

Strongly agree.

25. I am afraid to think about cervical cancer
Strongly disagree

Disagree

Neutral

26. Problems I would experience with cervical cancer would last a long time
Strongly disagree

Disagree

Neutral

Agree

Strongly agree.

27. Cervical cancer would threaten a relationship with my boyfriend, husband, or
partner.
Strongly disagree

Disagree

Neutral

Agree

Strongly agree.

Agree

Strongly agree.

28. If I had cervical cancer my whole life would change
Strongly disagree

Disagree

Neutral

29. If I developed cervical cancer, I would not live longer than 5 years
Strongly disagree

Disagree

Neutral
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Benefits
30. Having regular Pap Smear Tests will help to find changes to the cervix, before
they turn into cancer.
Strongly disagree

Disagree

Neutral

Agree

Strongly agree.

31. If cervical cancer was found at a regular Pap Smear Test its treatment would not
be so bad.
Strongly disagree

Disagree

Neutral

Agree

Strongly agree.

32. I think that having a regular Pap Smear Test is the best way for cervical cancer to
be diagnosed early.
Strongly disagree

Disagree

Neutral

Agree

Strongly agree.

33. Having regular Pap Smear Tests will decrease my chances of dying from cervical
cancer.
Strongly disagree

Disagree

Neutral

Agree

Strongly agree.

Barriers
34. I am afraid to have a Pap Smear Test for fear of a bad result.
Strongly disagree

Disagree

Neutral

Agree

Strongly agree.

35. I am afraid to have a Pap Smear Test because I don’t know what will happen.
Strongly disagree

Disagree

Neutral

Agree

Strongly agree.

Agree

Strongly agree.

36. I don’t know where to go for a Pap Smear Test.
Strongly disagree

Disagree

Neutral

37. I would be ashamed to lie on a gynecologic examination table and show my
private parts to have a Pap Smear Test.
Strongly disagree

Disagree

Neutral

Agree

Strongly agree.

Agree

Strongly agree.

Agree

Strongly agree.

38. Having a Pap Smear Test takes too much time.
Strongly disagree

Disagree

Neutral

39. Having a Pap Smear Test is too painful.
Strongly disagree

Disagree

Neutral

40. Health professionals doing Pap Smear Test are rude to women.
Strongly disagree

Disagree

Neutral

Agree

Strongly agree.

41. I neglect or cannot remember to have a Pap Smear Test regularly.
Strongly disagree

Disagree

Neutral

Agree

Strongly agree.

42. I have other problems more important than having a Pap Smear Test in my life.
Strongly disagree

Disagree

Neutral
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43. I am too old to have a Pap Smear Test regularly.
Strongly disagree

Disagree

Neutral

Agree

Strongly agree.

44. There is no health center close to my house to have a Pap Smear Test.
Strongly disagree

Disagree

Neutral

Agree

Strongly agree.

45. If there is cervical cancer development in my destiny, having a Pap Smear Test
cannot prevent it.
Strongly disagree

Disagree

Neutral

Agree

Strongly agree.

Agree

Strongly agree.

Agree

Strongly agree.

46. I prefer a female doctor to conduct a Pap smear.
Strongly disagree

Disagree

Neutral

47. I will never have a Pap smear if I have to pay for it.
Strongly disagree

Disagree

Neutral

Perceived Self-efficacy
48. I can arrange transportation to get to my Pap smear appointment.
Strongly disagree

Disagree

Neutral

Agree

Strongly agree.

Agree

Strongly agree.

Agree

Strongly agree.

Agree

Strongly agree.

49. I can arrange things in my life to have a Pap smear.
Strongly disagree

Disagree

Neutral

50. I can talk to people at the clinic about my concerns.
Strongly disagree

Disagree

Neutral

51. I can get a Pap smear even if I am worried.
Strongly disagree

Disagree

Neutral

52. I can get a Pap smear even if I don’t know what to expect.
Strongly disagree

Disagree

Neutral

Agree

Strongly agree.

Agree

Strongly agree.

Agree

Strongly agree.

53. I can find a way to pay for my Pap smear.
Strongly disagree

Disagree

Neutral

54. I can make an appointment for a Pap smear.
Strongly disagree

Disagree

Neutral

55. I know for sure that I can get a Pap smear if I really want to.
Strongly disagree

Disagree

Neutral

Agree

Strongly agree.

Agree

Strongly agree.

56. I know how to go about getting a Pap smear.
Strongly disagree

Disagree

Neutral
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57. I can find a place to get a Pap smear.
Strongly disagree

Disagree

Neutral

Agree

Strongly agree.

For questions 58- 63, please select the best answer.
Knowledge
58. The virus associated with cervical cancer is transmitted by:
a. Sexual intercourse
b. Blood transfusions
c. Inanimate objects
d. Talking
e. I don’t know
59. Cervical cancer and pre-cancer cells are associated with the presence of:
a. Epstein-Barr virus
b. Ebola virus
c. Human papillomavirus
d. Human immunodeficiency virus
d. I don’t know
60. Cervical dysplasia (abnormal cells) can be detected (found) by:
a. X-rays
b. Pap tests
c. Blood tests
d. Urine
e. I don’t know
61. Prevention of cervical cancer may require:
a. Delayed onset of sexual activity
b. Annual Pap test
c. Use of condoms
d. All of the above
e. I don’t know
62. Human papillomavirus (HPV) can cause:
a. Vaginal discharge
b. Genital warts
c. Itching
d. Burning urination
e. I don’t know
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63. HPV can live in the skin without causing growths or changes:
a. Yes
b. No
c. I don’t know
For questions 64 – 72, please identify which of the following are risk factors of
cervical cancer: (Answers: yes or no)
64. Multiple sex partners
a. Yes
b. No
65. Having genital warts/HPV
a. Yes
b. No
66. Sexual intercourse before age 18
a. Yes
b. No
67. Being immune suppressed
a. Yes
b. No
68. Having Chlamydia
a. Yes
b. No
69. Smoking cigarettes
a. Yes
b. No
70. Poor diet (low in fruits and vegetables)
a. Yes
b. No
71. Family history of cervical cancer
a. Yes
b. No
72. Use of oral contraceptives (birth control)
a. Yes
b. No
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73. Did your doctor or nurse practitioner at this clinic encourage you to get a Pap
smear?
a. Yes
b. No
74. Did your doctor or nurse practitioner at a different clinic encourage you to get a
Pap smear?
a. Yes
b. No
75. What or who encouraged you to get a Pap smear?
Please list your reason(s):
__________________________________________________________________
76. What prevented you from getting a Pap smear?
Please list your reason(s):
__________________________________________________________________
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77. Year of HIV diagnosis _____
78. Year of AIDS diagnosis _____
79. Patient status
a. New
b. Existing (old)
80. CD4 count _______
81. Viral load
a. Undetectable
b. Not undetectable
82. History of a hysterectomy
a. Yes
b. No
83. Height ______
84. Weight ______
85. Last Pap smear history _____
86. History of abnormal Pap test?
a. Yes
b. No
87. History of depression?
a. Yes
b. No
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